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ABSTRACT 
 
 
 Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy and 
comprises several distinct subtypes each with its own unique pathogenesis, clinical 
behavior, and response to therapy.  Chromosomal aberrations are a hallmark of ALL but 
alone fail to induce leukemia.  Pediatric ALLs can be divided into several categories 
based on the expression of several genetically conserved chromosomal translocations 
including the t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], MLL 
rearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage 
leukemia.  Each translocation confers a characteristic transforming phenotype within the 
cell in which it originates but is alone insufficient to induce overt leukemia.  In order to 
identify oncogenic lesions that cooperate with the aforementioned initiator lesions, we 
have performed genome-wide analysis of leukemia cells from 242 pediatric ALL patients 
using high resolution, single-nucleotide polymorphism microarrays.  Our analysis 
revealed deletion, amplification, point mutation, and structural rearrangements in genes 
encoding principal regulators of B lymphocyte development and differentiation in 40% of 
B-progenitor ALL cases.  The PAX5 gene was the most frequent target of somatic 
mutation, being altered in 31.7% of cases.  The identified PAX5 mutations resulted in 
reduced levels of PAX5 protein or the generation of hypomorphic alleles.  Deletions were 
also detected in TCF3 (also known as E2A), EBF1, LEF1, IKZF1 (IKAROS), and IKZF3 
(AIOLOS).  These findings suggest that direct disruption of pathways controlling B-cell 
development and differentiation contributes to B-progenitor ALL pathogenesis.  
Moreover, these data demonstrate the power of high-resolution, genome-wide approaches 
to identify new molecular lesions in cancer. 
 
The Philadelphia chromosome, a chromosomal abnormality that encodes BCR-
ABL1, is the defining lesion of chronic myelogenous leukemia (CML) and a subset of 
ALL.  To specifically define oncogenic lesions that cooperate with BCR-ABL1 to induce 
ALL, we subsequently performed genome-wide analysis of diagnostic leukemia samples 
from 304 individuals with ALL, including 43 BCR-ABL1 B-progenitor ALLs and 23 
CMLcases.  IKZF1 (encoding the transcription factor Ikaros) was deleted in 83.7% of 
BCR-ABL1 ALL, but not chronic-phase CML.  Deletion of IKZF1 was also identified as 
an acquired lesion at the time of transformation of CML to ALL (lymphoid blast crisis).  
The IKZF1 deletions resulted in haploinsufficiency, expression of a dominant-negative 
Ikaros isoform, or the complete loss of Ikaros expression.  Sequencing of IKZF1 deletion 
breakpoints suggested that aberrant RAG-mediated recombination is responsible for the 
deletions.  These findings suggest that genetic lesions resulting in the loss of Ikaros 
function are an important event in the development of BCR-ABL1 ALL. 
 
In order to assess the contribution of the loss of B-cell developmental regulatory 
genes with BCR-ABL1 we performed bone marrow transplant assays.  Pax5 
haploinsufficiency was shown to cooperate with BCR-ABL1 during leukemogenesis.  
Furthermore, as seen in human ALL, both Pax5 and p19Arf haploinsufficiency further 
cooperate during leukemogenesis.  Pathological analysis of the leukemias revealed a B-
lymphoid phenotype suggesting that this model results in the development of ALL.  
 viii 
Secondary transplant studies confirmed that this was ALL and not a lymphoproliferative 
disorder.  Immunophenotypic analysis confirmed the B-ALL phenotype and further 
revealed striking differences between Pax5
+/+
, Pax5
+/-
, and Pax5
-/-
 leukemias.  The 
leukemias that have lost either one or both Pax5 alleles revealed a more immature 
immunophenotype that was most pronounced in those with bi-allelic Pax5 loss.  The 
wild-type leukemias were consistent with a Hardy fraction C immunophenotype while 
the Pax5 null leukemias were akin to Hardy fraction A with no expression of any 
definitive B-cell surface antigens except B220 and CD43. 
 
The Pax5
+/+
 and Pax5
+/-
 leukemias were monoclonal while the Arf
+/-
 and the 
compound heterozygous (Pax5
+/-
 Arf
+/-
) leukemias were oligoclonal suggesting that the 
loss of p19Arf confers greater leukemogenic properties to a cell than does Pax5 loss. This 
is substantiated by the data that Arf heterozygous animals are tumor prone alone while 
Pax5 heterozygous animals live full normal lives. 
 
Genomic analysis of 50 murine leukemias (15 WT, 25 Pax5
+/-
 and 10 Arf
+/-
) 
revealed that some of the same genomic abnormalities found in human ALL also develop 
in our murine ALL model.  This finding suggests that our model is accurately 
recapitulating the development of human ALL.  Furthermore, we have found through 
extensive gene expression studies that our mouse BCR-ABL1 leukemias share a gene 
expression profile similar to human BCR-ABL1 leukemias further supporting our murine 
model of ALL. 
 
The gene expression studies that we have performed have also given us insight 
into the role that Pax5 haploinsufficiency may be playing during leukemogenesis.  
Recently D.J Wong et al performed an exhaustive study of embryonic and adult stem cell 
gene expression profiling.  He found that there are modules of genes that are common to 
either embryonic or adult stem cells.  He went further to delineate a group of genes that 
are commonly expressed in both murine and human embryonic stem cells and call this 
the core ESC-like module.  We performed gene set enrichment analysis (GSEA) using 
this core ESC-like module and found that this geneset is significantly enriched in our 
murine leukemias.  In addition, we found that this core ESC-like module was 
significantly enriched in normal Hardy fraction B cells, but not in A, or C-F.  We also 
found, using a principal component analysis method, that Pax5
+/+
 leukemias are most 
similar to Hardy fraction C while leukemias that have lost either one or both Pax5 alleles 
are most similar to Hardy fraction B suggesting that the loss of Pax5 blocks B-cell 
development and results in cells that are more similar to a stage that shares similar 
expression of embryonic stem cell genes.  Taken together this data suggests that by losing 
Pax5 the leukemia becomes more stem cell like and may gain advantages that other B-
cells do not because they continue down the road of differentiation. 
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CHAPTER 1 
GENERAL INTRDUCTION 
 
 
 Acute lymphoblastic leukemia (ALL) is the commonest pediatric malignancy 
accounting for 75% to 85% of all leukemia’s1 and occurs in roughly 31 per million 
children under the age of 15 each year.
2-4
 In contrast, adult ALL comprises 15% of 
leukemia’s with an annual incidence estimated at 22 per million in individual’s ≥25 years 
old (www.seer.cancer.gov). ALL is distinguished from lymphoblastic lymphoma by the 
presence of  ≥25% lymphoid blasts in the bone marrow. Currently, the World Health 
Organization (WHO) uses an integrated morphologic, immunologic, and cytogenetic 
disease classification system. The WHO also incorporates current knowledge of 
molecular lesions associated with different subtypes to help properly classify and risk 
stratify ALLs.
5
  According to the WHO classification system, ALLs can be divided in to 
several genetically distinct subtypes including B-progenitor leukemia’s with the 
translocations t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], MLL 
rearranged leukemia’s, hyperdiploid and hypodiploid karyotypes, and T-lineage leukemia 
(Figure 1-1).  These genetic lesions have been shown to be important in leukemia 
initiation
6
 but cooperating oncogenic lesions are required for leukemia development. 
  
 In an effort to identify cooperating oncogenic lesions, our laboratory has recently 
performed a genome-wide analysis of pediatric ALL using single nucleotide 
polymorphism microarrays (SNP).
7
  The SNP arrays allow us to investigate copy number, 
that is, the number of alleles that a leukemia has at a given genomic locus.  The SNP 
arrays also reveal information about genotype and copy number loss of heterozygosity 
(LOH).  LOH is a phenomenon that occurs when one allele undergoes gene conversion 
into another allele.  For example, if a leukemia had the following genotype at the PAX5 
locus AB; then one allele is A and the other is B.  When the leukemia develops, the SNP 
data may reveal that the leukemia shows a genotype of AA or BB at the PAX5 locus and, 
as a result, one can conclude that LOH has occurred at this locus.  Chapter 2 of this 
dissertation will outline the results of the SNP analysis.  Briefly, the SNP analysis 
identified mutations in genes encoding regulators of B-cell development and 
differentiation in 40% of B-progenitor ALL cases.  Of these genetic lesions, deletion of 
the transcription factor PAX5 was the most common mutation occurring in 32% of cases.  
The result of the PAX5 mutations was a reduction in the level of the transcription factor 
as a result of gene deletion/point mutation or generation of an altered form of PAX5 
protein. 
  
 Pax5, which is also known as B-cell specific activator protein (BSAP), is a 
transcription factor that is only expressed in the B lymphoid lineage of the hematopoietic 
system.
8
  Pax5 is a major regulator of B-cell development controlling the expression of 
many B-cell specific genes including Cd19, Blnk, Lef1, Ebf1, Cd79a, and Mb1.
9-14
  Pax5 
also controls the expression of alternate lineage genes such as Flt3, Notch1, Lmo2, and 
Cd28 by down regulating their expression.
15
  The expression of Pax5 is so important for 
proper B-cell development that loss of Pax5 results in an arrest in B-cell development at 
an early B-cell progenitor stage in Pax5
-/-
 mice.
16
  Interestingly, Pax5 is so important for
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Figure 1-1 Subtypes of pediatric acute leukemia 
 
Acute leukemia can be sub-divided into B-lineage and T-lineage leukemia’s based on cell 
surface antigen immunophenotyping.  B-lineage leukemia’s are more common than T-
lineage in children and can be subdivided into groups based on chromosomal 
abnormalities such as whole chromosome deletion, amplification, and chromosomal 
translocations.  These chromosomal abnormalities often have prognostic significance i.e.  
BCR-ABL and MLL rearranged leukemia’s carry a poor prognosis while hyperdiploid and 
TEL-AML1 leukemia’s are associated with better outcomes.  Adapted with permission. 
Pui, C, Relling, M, and Downing J. Acute lymphoblastic leukemia. New England Journal 
of Medicine 350, 1535-1548 (2004).
17
 3 
B-cell fate determination that B-cells from Pax5
-/-
 mice can dedifferentiate into alternate 
lineages.
18
  Chapter 2 of this dissertation will discuss the effects that Pax5 deletions and 
mutations have on the ability of Pax5 to transactivate the known Pax5 targets Cd19 and 
Cd79a. 
  
 The genome-wide SNP study that we performed revealed that regulators of B-cell 
development are deleted in 40% of ALLs with PAX5 being the most common target of 
mutation at 32% of cases.  The frequency and type of mutations varied by leukemia 
subtype, specifically, PAX5 was deleted in 13/47 (28%)  ETV6-RUNX1, 7/17 (41%) 
TCF3-PBX1, and 4/9 (44%) BCR-ABL1 ALL cases.
7
  Because the number of BCR-ABL1 
cases analyzed in the study was small, we subsequently analyzed 43 BCR-ABL1 ALLs 
including 21 pediatric and 22 adult cases
19
 (chapter 4).  The, now more robust, analysis 
revealed that 22/43 (51%) of BCR-ABL1 ALL cases harbored mutations in the PAX5 
gene.  Specifically, 12/21 (57%) of pediatric ALL and 10/22 (45%) of adult ALL cases 
harbored copy numbers abnormalities (CNA) at the PAX5 locus.  The PAX5 mutations 
resulted in the functional loss of one PAX5 allele, suggesting that PAX5 
haploinsufficiency may cooperate with BCR-ABL1 to induce ALL. 
  
 The BCR-ABL1 fusion, also known as, the Philadelphia chromosome (Ph), is the 
pathognomonic lesion in chronic myelogenous leukemia (CML).
20
  Ph positive leukemia 
also accounts for 5% of B-progenitor pediatric ALL and 40% of adult ALL, in addition to 
CML.
21,22
  The BCR-ABL1 fusion arises from the t(9,22)(q34;q11.2) translocation which 
leads to the fusion of the ABL proto-oncogene from chromosome 9 with the breakpoint 
cluster region (BCR) gene on chromosome 22.
23,24
  The generation of the Ph chromosome 
can lead to the formation of alternative products depending on the context of the 
leukemia.  The p210
BCR-ABL1 
and the p185
BCR-ABL1 
fusion proteins are typically found in 
CML and Ph+ ALL, respectively.
25-27
  The BCR-ABL1 protein encodes a constitutively 
active tyrosine kinase that is important for cell transformation.
26,28
  The Ph chromosome 
has also been shown to be an important negative prognostic indicator in both pediatric 
and adult ALL.
29-31
   
 
Chapter 3 will describe the generation of a p185
BCR-ABL1 
mouse model of ALL 
which will also incorporate the additional lesions that we have detected using the SNP 
analysis.  Specifically, both Pax5 and p19Arf haploinsufficiency will be modeled on the 
BCR-ABL1 background individually and together in order to assess their ability to 
cooperate with the Ph chromosome to induce ALL.  This model will be analyzed for 
additional cooperating events, as well as, assessed for its similarity to human Ph+ ALL 
using gene set enrichment analysis (GSEA).  The GSEA analysis will bring this 
dissertation full circle; from the identification of lesions in human ALL to mouse 
modeling of those lesions and the comparison of the effects that these lesions have on 
transcriptional networks in humans and in mice.  This analysis will allow us to better 
understand the human disease and will help us to move closer to developing therapeutics 
that will eventually cure children with ALL. 
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CHAPTER 2 
GENOME-WIDE ANALYSIS OF GENETIC ALTERATIONS IN ACUTE 
LYMPHOBLASTIC LEUKEMIA 
 
 
2.1 INTRODUCTION 
 
Pediatric acute lymphoblastic leukaemia (ALL) consists of genetically distinct 
subtypes including B-progenitor leukaemia’s with t(9;22)[BCR-ABL1], t(1;19)[TCF3-
PBX1], t(12;21)[ETV6-RUNX1], rearrangements of MLL, hyper- and hypodiploid 
karyotypes, and T-lineage leukaemia (T-ALL). These genetic lesions are important in 
leukemia initiation,
6
 but alone are insufficient to generate a full leukemic phenotype, 
suggesting that cooperating oncogenic lesions are required. Although additional 
mutations have been identified in a subset of cases, the full complement of cooperating 
lesions and their distribution within the known genetic subtypes of ALL remains to be 
defined. 
 
To obtain a comprehensive registry of genetic lesions in ALL, we examined DNA 
from the leukemic blasts of 242 cases of pediatric ALL using Affymetrix SNP arrays that 
interrogate over 350,000 loci and permit identification of copy number changes at an 
average resolution of less than 5kb. In addition, paired copy number and LOH analysis 
was performed for 228 ALL cases with matched remission samples. Our analyses 
identified a mean of 6.46 somatic copy number alterations per case, with deletions 
outnumbering amplification almost 2:1 (Table 2-1). The frequency of genomic deletions 
and amplifications varied significantly between ALL subtypes (Table 2-1). Genomic 
gains were frequent in B-progenitor ALL with high hyperdiploidy, but were rare in other 
B-ALL subtypes. By contrast, deletions were more frequent, ranging from 6 deletions per 
case in some genetic subtypes (ETV6-RUNX1 and hypodiploid ALL) to only a single 
deletion per case in MLL-rearranged ALL. 
 
 Fifty-four recurrent somatic regions of deletion were identified, with the minimal 
deleted regions typically measuring less than 1 Mb in size, and 24 of the deletions 
containing only a single gene. None were present in the germline samples. Although 
technical aspects of the methodology used could theoretically lead to false positive or 
negative results, FISH and/or qPCR confirmatory studies described below validated each 
of the examined lesions. The recurring deletions included 3p14.2 (FHIT),
32
 6q16.2-3 
(including CCNC),
33
 9p21.3 (two regions involving CDKN2A
34
 and MLLT3), 12p13.2 
(ETV6),
35
 11q23 (including ATM),
36
 13q14.2 (RB1)
37
 and 13q14.2-3 (including mir-16-1 
and mir-15a).
38
 In addition, deletions of other tumor associated genes not previously 
implicated in ALL were identified including LEF1, BTG1, and ERG. The most striking  
                                                 
 

 Adapted with permission. Mullighan C, Goorha S, Radtke I, Miller C, Coustan-Smith E, Dalton J, 
Girtman K, Mathew S, Ma J, Pounds S, Su X, Pui C, Relling M, Evans W, Shurtleff S, Downing J.  
Genome-wide analysis of genetic alterations in acute lymphoblastic leukemia.  Nature 446, 758-764 
(2007).
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Table 2-1 Frequency of genomic amplification and deletions in pediatric ALL 
 
Group Subtype 
N 
Amplifications 
mean ± SD (range) 
Deletions 
mean ± SD (range) 
All lesions  
mean ± SD (range)  
B-ALL Hyperdiploidy with >50 chromosomes 39 9.56 ± 3.59 (5-20) 1.59 ± 2.49 (0-11) 11.13 ± 5.0 (5-27) 
 TCF3-PBX1 17 1.59 ± 0.62 (1-3) 2.12 ± 1.17 (1-4) 3.7 ± 1.53 (2-7) 
 ETV6-RUNX1 47 0.89 ± 1.51 (0-8) 6.0 ± 4.63 (1-21) 6.68 ± 4.8 (0-21) 
 MLL rearranged 11 0.09 ± 0.3 (0-1) 0.91 ± 1.81 (0-6) 1 ± 1.79 (0-6) 
 BCR-ABL1 9 4 ± 5.3 (0-12) 4.2 ± 4.15 (0-12) 6.8 ± 4.52 (0-13) 
 Hyperdiploidy with 47-50 chromosomes 23 1.70 ± 1.55 (0-7) 3.5 ± 3.12 (0-12) 5.1 ± 4.31 (0-15) 
 Hypodiploid 10 1.1 ± 1.91 (0-6) 6.0 ± 4.42 (3-18) 7.1 ± 6.12 (3-24) 
 Other 36 1.06 ± 3.21 (0-19) 4.64 ± 5.14 (0-20) 5.58 ± 6.57 (0-23) 
 Total 192 2.97 ± 4.28 (0-20) 3.83 ± 4.2 (0-21) 6.63 ± 5.56 (0-27) 
           
T-ALL  50 0.9 ± 1.98 (0-9) 4.9 ± 6.21 (0-30) 5.8 ± 7.12 (0-39) 
           
All cases  242 2.54 ± 4.0 (0-20) 4.06 ± 4.69 (0-38) 6.46 ± 5.90 (0-39) 
 
Lesions exclude inherited copy number variations,
39
 as well as focal deletions arising from antigen receptor gene rearrangements at 
2p11.2 (IGKL), 7p14.1 (TRGV), 7q34 (TRBV), 14q11.2 (TRAV, TRDV, TRDJ, TRDC, and TRAJ), 14q32.33 (IGHV) and 22q11.22 
(IGLL). Homozygous deletions are scored as two lesions. There is significant variation in the mean number of amplifications 
(ANOVA P<0.0001), deletions (P<0.0001), and all lesions (P<0.0001) between B-progenitor ALL subtypes. Amplifications are more 
common in B-ALL than T-ALL (t test P=0.001).
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observation, however, was the identification of genomic alterations in genes that regulate 
B-lymphocyte differentiation in 40% of B-progenitor ALL cases. 
 
 
2.2 MATERIALS AND METHODS 
 
 
2.2.1 Patients and Samples 
 
Two hundred and forty two patients with acute lymphoblastic leukemia (ALL) 
treated at St Jude Children’s Research Hospital (SJCRH) between 1993 and 2005 were 
studied. These included precursor-B ALL with high hyperdiploidy (greater than 50 
chromosomes on karyotyping, HD>50, n=39), TCF3-PBX1 positive (E2A-PBX1, n=17), 
ETV6-RUNX1 positive (TEL-AML1, n=47), BCR-ABL1 positive (n=9), MLL rearranged 
(n=11), low hyperdiploidy (47-50 chromosomes, HD47-50, n=23), hypodiploidy (n=10), 
B-ALL with pseudodiploidy, near haploid karyotype, normal cytogenetics or non-
recurring cytogenetic abnormalities (n=36), and T-lineage ALL (T-ALL, n=50).  
 
Informed consent for the use of leukemic cells for research was obtained from 
patients, parents or guardians in accordance with the Declaration of Helsinki, and study 
approval was obtained from the SJCRH institutional review board. 
 
Mononuclear cells were purified from the diagnostic bone marrow or peripheral 
blood
 
samples by density gradient centrifugation and were cryopreserved
 
in liquid 
nitrogen. Diagnostic samples were characterized by conventional cytogenetics,
 
reverse 
transcriptase–polymerase chain reaction (RT-PCR) assays for BCR-ABL1, TCF3-PBX1 
[E2A-PBX1], and ETV6-RUNX1 [TEL-AML1], and for the presence
 
of MLL chimeric 
fusion genes by at least two of the following
 
methods: cytogenetics, 11q23 fluorescence 
in situ hybridization
 
(FISH), or RT-PCR for t(9;11)[MLL-AF9], t(11;19)[MLL-ENL], 
t(11;19)[MLL-ELL],
 
t(10;11)[MLL-AF10], or t(4;11)[MLL-AF4]. Remission samples 
were obtained from peripheral blood collected into EDTA vacutainer tubes at a median 
time of 200 days (range <1-3009) from diagnosis. 
 
DNA was extracted from diagnostic leukemia samples using the DNA Blood 
Mini Kit (Qiagen, Valencia, CA). DNA was quantified using either a Nanodrop 
Spectrophotometer or PicoGreen. Quality was assessed using the Nanodrop and by 
agarose gel electrophoresis. RNA was extracted from diagnostic samples using TRIzol 
(Invitrogen, Carlsbad, CA). Cells for FISH analysis were stored in Carnoy’s fixative. 
 
 
2.2.2 Affymetrix Mapping 100K and 500K Single Nucleotide Polymorphism Arrays 
 
Samples were genotyped with Affymetrix 50K GeneChip Human Mapping 50K 
Hind, 50K Xba, and 250K Sty arrays (Affymetrix, Santa Clara, CA). DNA was 
restriction enzyme digested, PCR-amplified, purified, labeled, fragmented and hybridized 
to the arrays according to the manufacturer’s instructions. Briefly, 250ng of DNA was 
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digested with XbaI, HindIII or StyI (New England Biolabs, Boston, MA). Digested DNA 
was adaptor-ligated and PCR-amplified using AmpliTaq Gold (Applied Biosystems, 
Foster City, CA) in four 100l PCR reactions for each enzyme-digested sample. PCR 
products from each set of four reactions were pooled, concentrated and fragmented using 
DNase I. Fragmented PCR products were then labeled, denatured and hybridized to the 
arrays. Arrays were then washed using Affymetrix fluidics stations, and scanned using 
the Gene Chip Scanner 3000. CEL files were generated using either Affymetrix 
GeneChip Operating Software v 3.0 or Affymetrix GeneChip Genotyping Analysis 
Software (GTYPE) v 4.0. SNP calls were generated using GTYPE. Affymetrix CEL and 
GTYPE-generated SNP call text files for the 242 blast samples, corresponding remission 
samples in those cases with PAX5 or EBF1 mutations, and the 62 remission samples used 
as diploid reference samples for copy number analysis have been deposited in NCBIs 
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible 
through GEO Series accession number GSE5511. 
 
 
2.2.3 Fluorescence In Situ Hybridization (FISH) Analysis 
 
Dual-color FISH was performed on archived bone marrow cells obtained at 
presentation, treated with Carnoy’s fixative and dried onto slides.  Probes were derived 
from bacterial artificial chromosome (BAC) clones (Children’s Hospital Oakland 
Research Institute, Oakland, CA.; Invitrogen; Open Biosystems, Huntsville, AL). BACs 
used were RP11-586B19 (EBF1 deletion), RP11-160B5 (EBF1 deletion, case Hypodip-
SNP-#5), RP11-96F2 (PAX5 deletion), CTD-2535J16 (PAX5 deletion), RP11-614P24 
and RP11-1136K1 (PAX5-ETV6 fusion), RP11-652D9 and RP11-79P21 (PAX5-FOXP1 
fusion), RP11-652D9 and RP11-73L12 (PAX5-ZNF521 fusion) RP11-652D9 (PAX5 
amplification in case Hypodip-SNP-#7), CTC-600N23 (IKZF3 deletion). BACs labeled 
for control probes were CTD-2194L12 (5p13.2), RP11-235C23 (9q31.2) and RP11-4F24 
(17p13.3). 
 
BAC clone identity was verified by T7 and SP6 BAC-end sequencing and by 
hybridization of fluorescently labeled BAC DNA with normal human metaphase 
preparations. BACs were labeled with either fluorescein isothiocyante or rhodamine 
fluorochromes. Target probes were paired with control probes from the opposite 
chromosomal arm where possible.  All probe mixtures were diluted 1:50 in DenHyb 
buffer (Insitus Biotechnologies, Albuquerque, NM) and co-denatured with the target cells 
on a hotplate at 90°C for 1 minute.  The slides were incubated overnight at 37°C on a 
slide moat and then washed in 50% formamide/1xSSC at 25°C for 5 minutes.  Nuclei and 
metaphases were counterstained with DAPI (200ng/ml) (Insitus Bio.) for viewing on 
either an Olympus BX60 or a Nikon Eclipse E800 fluorescence microscope equipped 
with a 100 watt mercury lamp; FITC, Rhodamine, and DAPI filters; a 100X PlanApo 
(1.40) oil objective; and a COHU CCD  or Photometrics SenSys camera.  Images were 
captured and processed with an exposure time ranging from 0.5-2 seconds for each 
fluorochrome using Cytovision v3.6 software from Applied Imaging (San Jose, CA).  
Images were captured and enhanced using Applied Imaging’s MacProbe v4.3 software. 
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2.2.4 Fluorescence Activated Cell Sorting 
 
Sorting of leukemic blasts according to level of CD10 expression was performed 
using a BD FACSAria Cell-Sorting System and a phycoerythrin-labeled anti-CD10 
antibody (BD Pharmingen, BD, Franklin Lakes, NJ). 
 
 
2.2.5 Genomic Sequencing 
 
 All 16 exons of EBF1 were sequenced using genomic DNA from 8 blast samples 
with EBF1 deletions and an additional 106 B-progenitor ALL cases without EBF1 
deletions. DNA was amplified using Accuprime Pfx DNA polymerase (Invitrogen) or 
Accuprime GC-rich DNA polymerase (Invitrogen). Exon sequences were determined 
aligning the reference EBF1 mRNA and DNA sequences (Genbank accessions 
NM_024007.2 and NC_000005.8). The coding regions of all 11 exons of PAX5 (exons 
1A, 1B, and 2-10) and the promoter region of exon 1B were sequenced in all 242 blast 
samples. Remission samples for patients with blast samples harboring PAX5 mutations 
were also sequenced. Primers were designed using Primer 3.
40
  PCR amplification was 
performed according to the manufacturer’s instructions using Eppendorf Mastercyclers 
(Eppendorf North America, Westbury, NY). Thermal cycling parameters for Accuprime 
Pfx DNA polymerase were 95°C for 2 minutes followed by 35 cycles of 95°C for 15 
seconds, 60°C for 30 seconds, and 68°C for 60 seconds. Thermal cycling parameters for 
Accuprime GC-rich DNA polymerase were 95°C for 3 minutes followed by 35 cycles of 
95°C for 30 seconds, 60°C (or annealing temperature as indicated in Supplementary 
Tables 3-5) for 30 seconds, and 72°C for 60 seconds, with a final extension of 10 minutes 
at 72°C. PCR products were purified using the Wizard SV Gel and PCR Clean-Up 
System (Promega, Madison, WI). PCR products were sequenced directly using Big Dye 
Terminator (v.3.1) chemistry on 3730xl DNA Analyzers (Applied Biosystems, Foster 
City, CA). Mutations detected by direct sequencing were confirmed by cloning PCR 
products into either pCR2.1-TOPO (Invitrogen) or pGEM-T Easy (Promega, Madison, 
WI) vectors, and sequencing multiple clones in both directions using M13 primers. 
 
 
2.2.6 Modeling of PAX5 Paired Domain Mutations 
 
A structural view of the PAX5 paired domain was generated by PyMOL v0.99 
(http://pymol.sourceforge.net/) using the coordinates of the X-ray structure of PAX5 
interacting with ETS1 on DNA, and PAX6 deposited with the Brookhaven Data Bank 
(PDB: 1K78 and 6pax; http://www.rcsb.org/pdb/).
41,42
 The protein sequences of the 
paired domains of PAX6 and PAX5 are 70.1% identical. 
 
 
2.2.7 Cell Culture 
 
 The human pre-B ALL cell lines Kasumi-2 and REH, the Burkitt lymphoma cell 
line Raji, and the T-lineage ALL cell lines Jurkat and MOLT-4 (all obtained from the 
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Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ, Braunschweig, 
Germany) were grown in RPMI-1640 containing 100
 
units/ml penicillin, 100 µg/ml 
streptomycin,
 
2 mM glutamine and 10% fetal bovine serum (20% for MOLT-4). 293T 
cells were maintained in DMEM containing 100
 
units/ml penicillin, 100 µg/ml 
streptomycin,
 
2 mM glutamine and 10% fetal bovine serum. 
 
 
2.2.8 Quantitative RT-PCR and Genomic PCR 
 
PAX5 gene expression of ALL samples was quantitated using Taqman® Assays-
on-demand Hs00277134_m1 (specific for PAX5 exons 4-5) and Hs00172001_m1 (PAX5 
exons 7-8) (Applied Biosystems, Foster City, CA). RNA was extracted using TRIzol 
(Invitrogen), and reverse transcribed using random hexamer primers and Superscript III 
Reverse Transcriptase (Invitrogen). Taqman® assays were performed using a 7500 Real-
Time PCR system and 7500 System Software (Applied Biosystems, Foster City, CA), 
using the 7500 universal cycling conditions: 50°C for 2 minutes, followed by 95°C for 10 
minutes, then 40 cycles of 95°C for 1 minute and 60°C for 1 minute.  
 
Standard curves for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and 
PAX5 gene expression were generated from 10-fold serial dilutions of the human t(12;21) 
[ETV6-RUNX1] REH cell line (American Type Culture Collection, Manassas, VA), 
which expressed high levels of PAX5 as determined by gene expression profiling using 
Affymetrix U133A chips (Affymetrix, Santa Clara, CA) (data not shown). These 
normalized ratios were compared to each other for differences in overall levels of PAX5 
expression. 
 
Primers for genomic quantitative PCR were designed using Primer Express 3.0 
(Applied Biosystems, Foster City, CA). Taqman® RNase P primers (Applied 
Biosystems, Foster City, CA) were used for control amplification. 200ng of leukemic 
blast DNA or control human DNA was amplified using the same conditions as those 
described for RNA real-time PCR. Standard curves for each PAX5 exon and RNase P 
were generated using normal human DNA. Assays were performed in duplicate. PAX5 
exon-specific copy numbers values were normalized by dividing the value obtained for 
PAX5 by the paired value obtained for RNase P for each sample.  Cutoffs of 0.7 and 0.3 
were used to identify hemizygous and homozygous PAX5 deletions, respectively. 
 
 
2.2.9 Detection of PAX5 in Leukemic Blasts by Flow Cytometry 
 
We characterized PAX5 expression in bone marrow mononuclear cells obtained 
at diagnosis from 16 patients with B lineage ALL. After density gradient separation, cells 
were labeled with anti-CD34 (of IgG2a class) conjugated to allophycocyanin (APC; 
Miltenyi Biotech, Auburn, CA) and anti-human CD19 (of IgM class; Research 
Diagnostics, Concord, MA) followed by goat-anti mouse IgM conjugated to 
phycoerythrin (PE; Jackson ImmunoResearch Laboratories, West Grove, PA). After cell 
permeabilisation with 8E, a paraformaldehyde-based reagent developed in the laboratory 
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of Dario Campana (SJCRH), cells were labeled with anti-human PAX5 (of IgG1 class; 
BD Transduction Labs, San Jose, CA) followed by goat anti-mouse IgG1 conjugated to 
fluorescein isothiocyanate (FITC; Southern Biotechnology Associates, Birmingham, AL). 
In parallel tests, anti-CD19 was omitted and cells were also labeled with a goat F(ab’)2-
anti-human IgM PE (Southern Biotechnology Associates, Birmingham, AL) after 
permeabilisation. Isotype-matched non-reactive antibodies were used as controls. We 
used the cell lines Raji and Kasumi-2 as positive controls for PAX5 staining; Molt-4 and 
Jurkat were used as negative controls. We analyzed 20,000 cells for each antibody 
combination using a FACSCalibur flow cytometer (BD Biosciences) and either 
CellQuestPro (BD Biosciences) or FlowJo (Treestar Inc, Ashland, OR) software. 
 
To show the B-cell specificity of the PAX5 antibody, we examined PAX5 
expression in peripheral blood mononuclear cells from a healthy donor. After density 
gradient separation, cells were labeled with anti-CD3 (of IgG2a class) conjugated to 
Pacific Blue (Invitrogen) and goat F(ab’)2-anti -human IgM PE. After cell 
permeabilisation with 8E, cells were labeled with the anti-human PAX5 antibody 
followed by goat-anti-mouse IgG1 FITC. In a parallel tube, we used an isotype-matched 
non-reactive control antibody (DakoCytomation, Carpinteria, CA) in place of PAX5 
followed by goat-anti-mouse IgG1 FITC (Southern Biotechnology Associates). We 
analyzed 10,000 cells using an LSR II flow cytometer (BD Biosciences) and 
CellQuestPro. The PAX5 antibody stained B-lymphocytes, but not T-lymphocytes.  
 
To demonstrate the PAX5-specificity of the anti-PAX5 antibody, we synthesized 
25 12mer overlapping peptides corresponding to the immunogen used to raise the PAX5 
antibody (residues 151-306). Peptides were synthesized using an Aapptec 396 Multiple 
Organic Synthesizer (Aapptec, Louisville, KY). Peptide purity and quality was assessed 
by high performance liquid chromatography (HPLC) and matrix assisted laser desorption 
ionization time of flight (MALDI-TOF) mass spectrometry. Peptide sequences are 
available upon request. PAX5, CD79A (Dako Cytomation) or mouse IgG1 antibody were 
preincubated with 15ng of either the PAX5 peptide pool or a non-PAX5 negative control 
peptide (corresponding to an internal sequence of SMAC) and then used to stain either 
peripheral blood mononuclear cells (PBMNCs) obtained from a normal donor or the Raji 
cell line. The PAX5 peptide pool specifically abolished staining of B lymphocytes by 
PAX5 but not CD79A. No blocking was seen with the control peptide and no reactivity 
with mouse IgG1 antibody was seen. These results demonstrate the PAX5 specificity of 
the anti-PAX5 antibody used for quantitation of leukemic blast intracellular PAX5 levels. 
 
 
2.2.10 Cloning of PAX5 and EBF1 Wild-Type and Mutant Alleles 
 
Total RNA was extracted from leukemia blast samples using TRIzol (Invitrogen) 
and 1g of total RNA was reverse transcribed using Superscript III (Invitrogen). The 
coding region of the exon 1a isoform of PAX5 was amplified using primers C282 and 
C302, the exon 1b isoform was amplified using primers C317 and C302, and the entire 
coding region of EBF1 was amplified using primers C503 and C504 using 1l of cDNA 
and the Advantage 2 PCR Kit (Clontech, Mountain View, CA). Thermal cycling 
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conditions were 5 cycles of 94°C for 30 sec and 72°C 3 min, followed by 5 cycles of 
94°C for 30 sec, 70°C for 30 sec and 72°C 3 min, followed by 25 cycles of 94°C for 30 
sec, 68°C for 30 sec and 72°C 3 min. PCR products were sequenced directly and after 
cloning into either pCR2.1-TOPO (Invitrogen) or pGEM-T Easy (Promega, Madison, 
WI) vectors. 
 
 
2.2.11 Identification, Detection, and Cloning of PAX5 Translocations 
 
The PAX5-ETV6 [PAX5-TEL] translocation was detected using primers 
PAX5ex3-F1 and ETV6ex3-R1 as previously described.
43
  The coding region of PAX5-
ETV6 mRNA was amplified using primers C282 and C283. 3’ rapid amplification of 
cDNA ends (RACE) was performed using the BD Smart RACE™ amplification kit 
(Clontech, Mountain View, CA) according to the manufacturer’s instructions, using the 
supplied universal primer mix and gene specific primers C294 (PAX5 exon 3) and C300 
(exon 1a). Nested PCR was performed using the supplied nested universal primer, and 
nested gene-specific primer C295. PCR products were gel-purified and sequenced 
directly and after cloning into pCR2.1-TOPO (Invitrogen). Following identification of 
PAX5-FOXP1 and PAX5-ZNF521 [PAX-EVI3] fusions by RACE, translocation-specific 
RT-PCR was performed using primers C303 and C304 for PAX5-FOXP1, and C303 and 
C309 for PAX5-ZNF521. The coding region of the PAX5-FOXP1 mRNA was amplified 
using primers C334 and C335, and PAX5-ZNF521 with primers C326 and C327, using 
Phusion™ High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, MA) and the 
following thermal cycling parameters: 98°C for 60 seconds, followed by 35 cycles of 
98°C for 10 seconds, 72°C for 90 sec (PAX5-FOXP1) or 3 minutes (PAX5-ZNF521) 
followed by a final extension step of 72°C for 10 min. 
 
 
2.2.12 Reporter Assays 
 
The coding regions of the exon 1a isoforms of wild type PAX5 and PAX5 
mutations, deletions and fusions were cloned into the XhoI site of the MSCV-IRES-
mRFP (MIR) vector by blunt-ended ligation. This vector was created by replacing the 
green fluorescent protein (GFP) cassette of the MSCV-IRES-GFP vector
44
 with a 
monomeric red fluorescent protein cassette
45
 (kindly provided by Martine Roussel of St 
Jude Children’s Research Hospital, Memphis, TN). Twenty-four hours after plating, 
2x10
5
 293T cells were transfected with 1g of wild-type MIR-PAX5, mutant MIR-
PAX5 or MIR without PAX5 plasmid DNA, 1 g of luc-CD19 reporter plasmid DNA 
(kindly provided by Meinrad Busslinger, Vienna, Austria),
46
 and 0.1 g of pRL-TK 
Renilla luciferase plasmid DNA (Promega) using FuGENE 6 (Roche Diagnostics, 
Alameda, CA). Forty-eight hours post-transfection, cell lysis and measurement of firefly 
and Renilla luciferase activity was performed using the Dual-Luciferase® Reporter 
Assay System (Promega) according to the manufacturer’s instructions. Transfections 
were performed in triplicate. The firefly luciferase activity was normalized according to 
corresponding Renilla luciferase activity, and luciferase activity was reported as mean (± 
s.e.m.) relative to the luc-CD19/PAX5 WT transfection. For competition assays, in which 
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increasing amounts of either PAX5-ETV6 or PAX5-FOXP1 vector was transfected with 
fixed amounts of PAX5 wild type vector, “empty” MSCV-IRES-mRFP vector was also 
used to maintain a constant mass of expression vector in each experiment. 
 
 
2.2.13 Electrophoretic Mobility Gel-Shift Assays 
 
Nuclear extracts of 293T cells transfected with wild type PAX5 or PAX5 mutant 
alleles were prepared using the method of Andrews and Faller.
47
 Equivalent expression of 
each PAX5 variant was confirmed by western blotting of nuclear extracts (data not 
shown). Two micrograms of protein was incubated with [-32P]ATP end-labeled double-
stranded oligonucleotides containing a CD19 promoter PAX5 binding site
10
 using the Gel 
Shift Assay System (Promega). A mutated CD19 binding site was used as a non-specific 
competitor. Complexes were supershifted using a PAX5 N-terminus specific rabbit 
polyclonal antibody (Chemicon, Temecula, CA) and were resolved using 6% DNA 
retardation gels (Invitrogen). 
 
 
2.2.14 Western Blotting 
 
Four million leukemic blasts were washed with PBS and lysed with 4x LDS 
sample buffer (Invitrogen). For nuclear extracts, 10l of nuclear lysate was blotted. 
Lysates were separated using NuPAGE 10% Bis-Tris gels, transferred to nitrocellulose 
membranes, and after blocking were incubated with N-terminal (Chemicon) or C-
terminal PAX5 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), C-terminal 
Actin (Santa Cruz), and as a control for blotting of nuclear extracts, N-terminal DEK 
antibody (BD Biosciences). Nuclear extracts of 558LM cells were incubated with 
PCNA antibody (Santa Cruz). Following incubation with secondary antibody, blots were 
developed using the SuperSignal West Femto Max Sensitivity Substrate 
chemiluminescent reagent (Pierce, Rockford, IL) and exposed to film or captured using a 
ChemiDoc XRS gel imaging system (Bio-Rad Laboratories, Hercules, CA). 
 
 
2.2.15 Transduction and Analysis of IgM Expression by 558LµM Cells 
 
The terminally differentiated B-cell line 558LM is a derivative of the J558L 
plasmacytoma cell line stably transfected with a construct expressing three of four 
components required for surface IgM expression: IgM heavy chain, immunoglobulin 
lambda light chain, and Ig-The cells do not express mb-1, hence the cells do not 
produce Ig- and surface IgM is not expressed. mb-1 expression is dependent on Pax5, 
thus following transduction of 558LM cells with ecotropic retroviruses expressing 
PAX5, surface IgM expression serves as a useful readout of the transactivating activity of 
PAX5 variant alleles. 
 
558LM cells were grown in RPMI 1640 media (Invitrogen) supplemented with 
10% fetal bovine serum (Hyclone, Logan, UT), 2mM L-glutamine (Invitrogen), 50mg/ml 
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gentamicin (Invitrogen), 0.3g/ml Xanthine (Sigma, St Louis, MO), and 1g/ml 
mycophenolic acid (Sigma) as previously described.
48
 The Phoenix packaging system 
was used to generate ecotropic retrovirus expressing PAX5 cloned into either the MSCV-
IRES-mRFP or MSCV-IRES-YFP constructs, as described above. 500,000 558LM cells 
were transduced in six-well dishes with 3 ml of retroviral supernatant and 8g/ml 
polybrene. One day post transduction cells were transferred to 10ml of fresh media. Cells 
were harvested for flow cytometric analysis and fluorescence activated cell sorting 
(FACS) day 3 post transduction. 
 
Samples were stained with fluorescein isothiocyanate conjugated anti-mouse IgM 
(Southern Biotechnology Associates, Birmingham, AL) and a rat IgG2a isotype control 
antibody (BD Pharmingen) on a FACSVantage SE (BD Biosciences). 100,000 viable 
events were collected for analysis. IgM expression was analyzed in the RFP or YFP 
positive populations. Two million RFP-positive cells were flow sorted for western 
blotting. 
 
 
2.2.16 Methylation Analysis 
 
Methylation status of the promoter regions of EBF1, PAX5 exons 1a and 1b, and 
IKZF1 (Ikaros) was analyzed by matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) of PCR-amplified, bisulfite-modified leukemic 
blast DNA, as previously described (Sequenom, San Diego, CA).
49,50
 This method allows 
semiquantitative, high-throughput analysis of methylation status of multiple CpG units in 
each amplicon generated by base-specific cleavage. 
 
Ninety-six samples were examined. PCR reactions were designed using annotated 
CpG island data obtained from the University of California Santa Cruz genome browser. 
The PAX5 gene contains several CpG islands, one of which (Chr 9:37024136-37028341) 
lies upstream of the coding region of PAX5 exon 1a. Two amplicons were used to 
examine this region: X014_PAX5 lies immediately upstream of the PAX5 exon 1a coding 
region in the known regulatory region of the PAX5 promoter;
51,52
 X019_PAX5 lies is 
further upstream in the same CpG island. Amplicon X021_PAX5 is located in the CpG 
island (Chr 9 37016223-37018014) upstream of the coding region of PAX5 exon 1b. 
Methylation data for each amplicon was viewed in GeneMaths XT v 1.5 (Applied Maths, 
Austin, TX). To compare methylation levels between ALL subtypes, the mean 
methylation levels of CpG units in each amplicon was calculated for each patient. Mean 
methylation levels for each amplicon were then compared across ALL subtypes by one-
way ANOVA, and Dunn’s post-hoc test. 
 
 
2.2.17 Gene Set Enrichment Analysis 
 
GSEA
53
 considers the genome-wide expression profiles of two classes of samples 
(here, PAX5-mutated and PAX5-wild-type). Genes are ranked based on correlation 
between expression and class distinction. GSEA then determines if the members of a 
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gene set S are randomly distributed in the ranked gene list L, or primarily found at the top 
or bottom. An enrichment score ES is calculated that reflects the degree to which a gene 
set is overrepresented at the top or bottom of the entire ranked list L. The ES is a running 
sum, Kolmogorov-Smirnov like statistic calculated by walking down list L and increasing 
the statistic when a gene in S is encountered, and decreasing it when it is not. The 
magnitude of the increment depends on the strength of association with phenotype, and 
the ES is the maximum deviation from zero encountered in the random walk. The 
significance level of ES is calculated by phenotype-based permutation testing, and when 
a database of gene sets are evaluated, as in this analysis, the significance level is adjusted 
for multiple hypothesis testing by calculation of a false discovery rate FDR.  
 
 
2.3 RESULTS 
 
 
2.3.1 Focal Deletions of EBF1 in B-ALL 
 
Eight B-progenitor ALL cases harbored mono-allelic deletions of  EBF1 (early B-
cell factor), with deletions limited to this gene in 6 cases (Figure 2-1A-B). EBF1 is 
required for the development of B cells, and with E2A regulates the expression of B-
lineage specific genes. Mice null for Ebf1 arrest B cell development at the pro-B cell 
stage, whereas Ebf1
+/-
 mice have a 50% reduction in the number of mature B cells but a 
normal number of pro-B cells.
54
 These observations suggest that EBF1 
haploinsufficiency may contribute to leukemogenesis. In support of this interpretation, 
FISH analysis of one case revealed two populations of blasts, one with mono-allelic and 
the other with bi-allelic EBF1 deletions (Figure 2-1C). Flow cytometric analysis of this 
case demonstrated two distinct blast populations, an immature pro-B cell like 
CD10
dim
CD22
dim
 population and a more mature CD10
bright
CD22
+
 population (Figure 2-
1D). These populations significantly differed in expression of CD79A (MB-1), a 
transcriptional target of EBF1 (Figure 2-1E). Remarkably, FISH on sorted blasts revealed 
homozygous deletion of EBF1 in the immature CD10
dim
 fraction, and hemizygous EBF1 
deletions in the more mature CD10
bright
 fraction (Figure 2-1F). Thus, these data suggest 
that deletion of EBF1 in these cases may contribute to the block in differentiation that is a 
hallmark of ALL. 
 
In ALL cases with mono-allelic deletion of EBF1, expression of the wild-type 
EBF1 allele was detected by RT-PCR consistent with haploinsufficiency. Moreover, no 
evidence of promoter methylation  or point mutations of EBF1 was detected (data not 
shown).
49
 
 
 
2.3.2 A High Frequency of Mono-Allelic PAX5 Deletions in B-ALL 
 
We next examined the cohort for abnormalities in other genes within the B-cell 
development pathway. Remarkably, we identified copy number changes in PAX5 in 57 of 
192 (29.7%) B-progenitor ALL cases (mono-allelic loss in 53, biallelic loss in 3, and an 
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Figure 2-1 EBF1 deletions in B-progenitor ALL 
 
A, EBF1 exons are indicated by vertical lines. The extent of EBF deletion in each case is 
shown by a horizontal line, with large deletions denoted by arrowed lines. *FISH analysis 
for case BCR-ABL-SNP#5 is shown in C. B, Copy number heatmap showing EBF1 
deletion in 8 B-ALL cases. Ph, BCR-ABL1 positive; H, hypodiploid; O, other. C, EBF1 
FISH of case BCR-ABL-SNP#5 identifies two distinct blast populations, with either 
mono-allelic or bi-allelic EBF1 deletion; the EBF1 probe is red and the control probe is 
green. D, Two distinct blast populations differ in surface expression of CD22 and CD10. 
E, Correlation of blast CD79A and CD10 expression. F, FISH analysis of cells sorted by 
CD10 expression.
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internal amplification in 1, Figure 2-2). PAX5 is essential for B-lineage commitment and 
maintenance
55
 and acts downstream of E2A and EBF1 to activate expression of B-lineage 
specific genes such as CD19, CD79A, BLNK and CD7, and to repress expression of 
alternate lineage genes.
56,57
 Four patterns of PAX5 deletion were identified (Figure 2-2B): 
(1) focal deletions involving only PAX5 (25 cases), (2) broader deletions involving PAX5 
and a variable number of flanking genes (7 cases), (3) large 9p deletions involving the 3’ 
portion of PAX5, (5 cases) and (4) deletion of all of chromosome 9 or 9p (19 cases). The 
PAX5 deletions and amplification were confirmed by FISH and/or genomic qPCR. 
Importantly, FISH demonstrated that, with rare exception, the PAX5 deletions were 
present in a dominant leukemic clone, consistent with a role in leukemogenesis.  
 
Of 25 B-progenitor ALLs with deletions confined to PAX5, 23 deleted only a 
subset of PAX5 exons, resulting in the expression of internally deleted transcripts. In nine 
cases, in-frame splicing across the deletions would be predicted to encode an internally 
deleted PAX5 protein that either lacks the DNA-binding domain and/or transcriptional 
regulatory domains. Western blot analysis in cases with sufficient material revealed 
expression of the predicted size mutant PAX5 protein (Figure 2-2 D-E and data not 
shown). The other transcripts are predicted to encode prematurely truncated proteins 
lacking key PAX5 functional domains. The focal amplification of PAX5 exons 2-5 in 
case Hypodip-SNP-#7 is predicted to abolish expression of normal PAX5 from the 
amplified allele. Thus, of the 57 cases with PAX5 copy number changes, the majority 
either lack expression of PAX5 from the altered allele (27 cases), produce proteins that 
lack the DNA-binding domain (22 cases), or transcriptional regulatory domain (7 cases), 
or have a bi-allelic promoter mutations (one case), suggesting that these genetic 
alterations primarily result in loss-of-function. 
 
Flow cytometry performed on leukemic blasts in 17 cases demonstrated an 
approximately twofold reduction in the level of wild-type PAX5 protein in cases with 
mono-allelic deletions, suggestive of haploinsufficiency. Consistent with this 
interpretation, PAX5 mRNA levels were quantitated in 46 B-ALL cases (26 wild-type, 20 
mutated), and were found to be reduced in cases with PAX5 deletions. A small number of 
PAX5 wild-type cases also had low PAX5 mRNA levels, raising the possibility of 
epigenetic PAX5 silencing in these cases. 
 
 
2.3.3 Cryptic Translocations and Point Mutations of PAX5 in B-ALL 
 
Five B-progenitor ALL cases had large 9p deletions extending into the 3’ portion 
of PAX5. Two had rearrangements of chromosomes 9 and 12, either as a dic(9;12) or a 
t(9;12), and were shown by FISH and RT-PCR to harbor the previously described PAX5-
ETV6 fusion
43,58
 (Figure 2-3A-B). Rapid amplification of cDNA ends identified novel 
PAX5 chimeric transcripts in two of the remaining three cases: fusion of PAX5 exon 6 to 
exon 7 of the forkhead box P1 gene (FOXP1), and fusion of PAX5 exon 7 to exon 4 of 
the zinc finger protein 521 gene (ZNF521, the human homolog of murine Evi3) (Figure 
2-3A). These were confirmed by FISH (Figure 2-3C-D), RT-PCR, and sequencing. The 
PAX5-ETV6 fusion was also detected as a 65kDa protein in both cases containing this 
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Figure 2-2 PAX5 deletions in ALL 
 
A, PAX5 exons and domains. PD, paired domain; O, octapeptide; H, homeodomain-like; 
TD-A, transactivation, activating; I, transactivating, inhibitory. B, Extent of PAX5 
deletions: hemizygous, solid line; homozygous, dashed; amplification, red; beyond region 
shown, arrowed; *deletion confined to PAX5. C, PAX5 copy number heatmap for 20 
ALL cases and corresponding germline samples. PAX5 exon-specific copy number as 
defined by quantitative genomic PCR is also shown. Amp, amplified; CN, copy number; 
T-P, TCF3-PBX1; H, homozygous; N, normal (remission sample); Ph, BCR-ABL1; T, T-
ALL. D-E, Schematic of PAX5 mutations and western blot of primary leukemic blasts 
(mutant PAX5 proteins indicated by arrows).
 18 
 
 
 
Figure 2-3 PAX5 translocations in B-progenitor ALL   
 
A, Schematic of PAX5 translocation-encoded fusion proteins. Breakpoints are indicated 
by (↓); bp, base pairs; BRE, BMP2 response element domain; EBF, EBF-interaction 
domain; ETS, Ets domain; C and CC, coiled-coil domain; FH, forkhead domain; H, 
homeodomain-like; HLH, helix-loop-helix; O, octapeptide domain; PD, paired domain; 
SMAD, SMAD-interacting domain; Zn, zinc finger domain. B-D, Interphase FISH for 
PAX5-ETV6 (B), PAX5-FOXP1 (C) and PAX5-ZNF521 (D). The PAX5-specific probe is 
red, and the partner genes green; arrows denote the fusions. e, Location of missense (▼), 
insertion/deletion (●), frameshift (♦) and splice-site (►) PAX5 mutations.
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rearrangement (Figure 2-2E); primary patient material was not available for western blot 
analysis for the PAX5-FOXP1 and PAX-ZNF521 cases. An additional 50 cases were 
screened by RT-PCR for the three translocations and no additional cases were identified. 
 
Each of these PAX5 chimeric genes fuse the DNA-binding paired domain of 
PAX5 to the DNA-binding and transcriptional regulatory domains of the partner proteins 
(Figure 2-3A). Thus, the fusion proteins are predicted to retain the ability to bind to 
PAX5 transcriptional targets, but would no longer provide normal transcriptional 
regulatory functions. The fusion proteins may also influence the expression of genes 
normally regulated by the partner protein, each of which has been implicated in B cell 
development or hematopoietic malignancies.
59-63
  
 
Sequencing of PAX5 identified point mutations in 14 cases that clustered in exons 
encoding the DNA-binding or transcriptional regulatory domains (Figure 2-3E). In 13 
cases with available germline DNA, the mutations were shown to be somatically 
acquired. Moreover, a quantitative analysis suggested that the mutations were present in 
all blasts in 12 of 14 cases, and in a major subclone in the remaining two cases. The point 
mutations were hemizygous except in one case where a homozygous splice-site mutation 
(IVS9+1) of  PAX5 was detected within an extensive region of 9p LOH that included a 
homozygous deletion of CDKN2A. 
 
Nine PAX5 mutations were identified within exons encoding the paired DNA-
binding domain: V26G, P34Q, P80R, and the insertion/deletion NDTVP126RA (Figure 
2-3E). Modeling studies using the PAX5 crystal structure
41
 suggests that each mutation 
should impair DNA-binding. Other mutations consist of frame-shift, splice site, or 
missense mutations that affect the transactivation domain, and a single case with an exon 
1B frame-shift mutation that results in a prematurely truncated 10 residue polypeptide 
(Figure 2-3E). Collectively, the identified PAX5 mutations are predicted to result in lost 
or altered DNA-binding or transcriptional regulatory function.   
 
We also assessed whether methylation-induced silencing of PAX5 occurs in B-
progenitor ALL using mass spectrometry.
10
 These data revealed high-level PAX5 
promoter methylation in T-ALL, but minimal methylation in B-progenitor ALLs, 
irrespective of PAX5 mutational status. Thus, epigenetic silencing due to high-level 
methylation does not appear to be a prominent mechanism of PAX5 silencing in B-
progenitor ALL. 
 
 
2.3.4 Functional Consequences of PAX5 Mutations 
 
To assess the DNA-binding and transcriptional activity of a subset of the 
identified PAX5 mutants, luciferase-based reporter assays were performed using the 
PAX5-dependent reporter plasmid, luc-CD19.
46
 Each of the PAX5 mutants tested 
displayed significantly reduced transcriptional activation compared to wild-type PAX5 
(Figure 2-4 A-B and Figure 2-5). Moreover, transfection of increasing amounts of PAX5-
ETV6 or PAX5-FOXP1 together with a fixed amount of wild-type PAX5 demonstrated 
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Figure 2-4 Impaired function of PAX5 mutants   
 
A, Structure of PAX5 variants. B, transcriptional activity of PAX5 variants using the luc-
CD19 reporter. Bars show mean (± s.e.m.) luciferase activity of triplicate experiments 
normalized to luciferase activity of wild-type (WT) PAX5. **ANOVA with Dunnett’s 
test P<0.01 c.f. WT PAX5. C, representative flow plots of 558LM cells transduced with 
PAX5-expressing retrovirus, showing reduced sIgM expression of PAX5 mutants c.f. 
WT PAX5. Percents indicate proportion of mRFP+ cells that are sIgM+. D, mean (± 
s.e.m.) 558LM sIgM expression of triplicate experiments, normalized to sIgM 
expression of PAX5 WT transduced 550LM cells. E, Impaired sIgM expression is 
corrected following co-infection with WT PAX5 virus (WT) for the PAX5 deletion and 
point mutants, but not PAX5-ETV6.
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Figure 2-5 PAX5 western blots of 293T cells used for CD19-luc reporter assays  
 
Western blots using an N-terminus PAX5 specific antibody (Chemicon) were performed 
on nuclear extracts of transiently transfected 293T cells. Neither this antibody, nor any of 
the alternative available PAX5 specific antibodies detect the PAX5 Δ2-6 or Δ2-8 internal 
truncation mutants.
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that the fusion proteins competitively inhibit the transcriptional activation of wild-type 
PAX5 (Figure 2-6). Analysis of DNA-binding activity revealed a marked reduction in 
binding activity for PAX5 variants with paired domain mutations or deletions (Figure    
2-7).  
 
We next examined the effect of PAX5 mutations on transcriptional activation of 
the PAX5 target Cd79a (mb-1, Ig-) in the murine plasmacytoma cell line 558LM.
23
 
This cell line expresses three of four components of the surface IgM (sIgM) receptor 
complex ( heavy chain,light chain, and Ig-), but not Cd79a or Pax5, and consequently 
does not express sIgM. Following transduction with PAX5-expressing retrovirus, Cd79a 
and thus sIgM are expressed, and quantitation of sIgM serves as a sensitive measure of 
the Cd79a transactivating activity of PAX5.
48
 This assay confirmed the reduced 
transcriptional activity of the PAX5 mutants (Figure 2-4C-D and Figure 2-8). Co-
transduction with wild-type and mutant PAX5 retroviruses showed that PAX5 wild-type 
virus restored sIgM expression in the presence of the P34Q, P80R or 6-8 PAX5 variants, 
but incompletely with PAX5-ETV6 (Figure 2-4E and Figure 2-9). This suggests that the 
PAX5 DNA-binding and internal deletion mutants act as hypomorphic alleles with weak 
competitive activity, where as PAX5-ETV6 acts as a stronger competitive inhibitor of 
wild-type PAX5.  
 
As the PAX5 mutations are predicted to reduce or inhibit normal PAX5 functional 
activity, we next examined expression of PAX5 target genes in leukemic blasts. We did 
not observe a correlation between PAX5 mutation status and expression of the PAX5 
targets CD19 and CD79A.
11,57
 However, using Affymetrix HG-U133A gene expression 
profiling data,
64
 we identified a 42 gene expression signature for PAX5-mutated ETV6-
RUNX1 B-ALL that included both up-regulated (PAX5 repressed) and down-regulated 
(PAX5 stimulated) genes (Figure 2-10A). PAX5-stimulated genes included the known 
PAX5 target CD72
57
 as well as genes with known roles in oncogenesis (e.g. DAPK1,
65
 
TACC1
66
). We then performed cross-subtype gene set enrichment analysis (GSEA)
53
 to 
test for enrichment of these putative PAX5-regulated genes in non-ETV6-RUNX1 B-ALL 
cases. This analysis demonstrated highly significant enrichment of the PAX5 stimulated 
genes in PAX5 wild-type B-progenitor ALL cases that lacked recurrent cytogenetic 
abnormalities, and in PAX5 wild-type cases from the entire non-ETV6-RUNX1 B-
progenitor ALL cohort (Figure 2-10B-C). This suggests that the identified PAX5 
mutations have a significant effect on the intracellular transcriptional network within 
primary leukemic cells. 
 
 
2.3.5 Pattern of B-Cell Development Gene Mutations in ALL 
 
Deletions of additional genes encoding regulators of B-cell development were 
identified, including IKZF1 (Ikaros, 17 B-progenitor ALL cases), IKZF3 (Aiolos, N=3), 
LEF1 (N=3) TCF3 (N=1) and BLNK (N=2). Genomic sequencing of IKZF1 was 
performed in all cases and no mutations were identified.
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Figure 2-6 PAX5 translocations competitively inhibit the transcriptional activity of 
wild-type PAX5 
 
Relative luminescence of 293T cells transfected with luc-CD19, fixed amount of PAX5 
WT and increasing amounts of PAX5-ETV6, A, or PAX5-FOXP1, B, plasmids. Empty 
MSCV-IRES-mRFP (MIR) expression vector was used to maintain a constant mass of 
DNA in each transfection experiment. Luminescence is normalized to Renilla luciferase 
activity and is shown relative to 293T cells infected with empty MIR vector. Bars show 
means ± SEM of triplicate experiments. *ANOVA with Dunnett’s test P<0.05; **P<0.01. 
Importantly, expression of the various PAX5 mutants did not inhibit the transcription of 
the pRL-TK Renilla luciferase plasmid used as an internal control for transfection 
efficiency.
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Figure 2-7 DNA-binding of PAX5 mutant alleles   
 
Gel-shift assay showing reduced (P80R) and normal (6-8) binding of PAX5 variants to 
a CD19 promoter binding site. ab, supershift with PAX5 antibody; wt, wild-type and mt, 
mutant competitor oligonucleotides; -, no antibody or competitor oligonucleotides.
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Figure 2-8 PAX5 mutations impair CD79A transactivation of sIgM expression in the 
558LµM cell line  
 
558LM cells were transduced with MSCV-PAX5-IRES-mRFP retroviruses expressing 
wild type or mutant PAX5. sIgM expression of the mRFP-positive population was 
measured. Four experiments examining different PAX5 variants were performed (A-E, 
F-J, K-P and Q-T). Empty vector (MIR) and wild-type PAX5 (PAX5 WT) were 
included as controls in each experiment. All transductions were performed in triplicate, 
and representative flow plots are shown. Percentages refer to the proportion of RFP+ 
cells expressing sIgM. Two million RFP+ cells were sorted from a transduction 
experiment for each PAX5 variant, and western blotting for PAX5 and the control 
antigen PCNA performed on nuclear extracts of the RFP+ population. Sort purities were 
>90%. Western blot analysis confirmed comparable protein expression of the PAX5 
variants analyzed, with the exception of PAX5-ETV6, which is larger than the other 
variants (approx. 65kDa c.f. 45 kDa for WT PAX5), and is consistently expressed at 
lower protein levels than the other variants. The PAX5 antibody used (BD Transduction 
Labs) was raised against an internal PAX5 epitope and does not recognize the 2-6 or 
2-7 PAX5 internal deletion mutants shown in P.
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Figure 2-9 Design of 558LµM PAX5 WT and mutant co-transduction experiments 
 
558LM cells were co-transduced with bicistronic MSCV retroviruses co-expressing 
wild type PAX5 with YFP, and mutant PAX5 alleles with mRFP. Surface IgM 
expression was then quantitated on the dual positive population.
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Figure 2-10 Cross-subtype gene set enrichment analysis of PAX5-regulated genes in 
B-ALL 
 
A, heatmap of 42 differentially expressed genes (at FDR <0.3) in ETV6-RUNX1 PAX5-
deleted v. ETV6-RUNX1 PAX5 wild-type ALL. B, GSEA showing significant enrichment 
of the PAX5-stimulated genes shown in B-ALL samples lacking recurring cytogenetic 
abnormalities. The ranked gene list of PAX5-wild-type v. PAX5-deleted cases is shown in 
the lower, grey plot. Vertical blue lines indicated where probe sets in the PAX5-
stimulated gene set fall in the ranked gene list. The top, red line indicates the running 
enrichment score (ES) that becomes more positive as probe sets are encountered at the 
top of the list. C, significant enrichment for PAX5-stimulated genes in all non-ETV6-
RUNX1 B-progenitor ALL. Enrichment for the PAX5-repressed gene set in PAX5-
mutated cases was also observed in both non-ETV6-RUNX1 cohorts, but was not 
significant (i.e. FDR>0.25) after correction for multiple hypothesis testing.
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 Importantly, there were marked differences in the frequency and type of 
mutations among genetic subtypes of ALL. Specifically, all 10 hypodiploid cases had one 
null PAX5 allele, and six of these also had either a point mutation (N=5) or translocation 
(PAX5-ZNF521, N=1) involving the other PAX5 allele. Five of these cases also contained 
deletions in other B-cell development genes, with up to three different genes being 
mutated within a single case. In contrast, 28% of the ETV6-RUNX1 cases contained focal 
mono-allelic PAX5 deletions but lacked evidence of mutations in the retained PAX5 
allele. Three of these cases also had deletions of a single allele of EBF1, and another two 
cases had deletions of only EBF1. At the other end of the spectrum, mutations in B-cell 
development genes were uncommon in hyperdiploid B-progenitor ALL (13% of cases). 
 
 
2.4 DISCUSSION 
 
Understanding the molecular pathogenesis of cancer requires a detailed 
cataloguing of all genetic lesions within a cancer cell. The data presented here provide a 
rational roadmap for approaching such a task. We have shown that genomic copy number 
analysis using high-density SNP arrays can pinpoint altered genes and pathways for 
further analysis. This approach led to the unexpected finding of mutations in genes 
encoding regulators of B cell development and differentiation in 40% of B-progenitor 
ALLs. The identified genetic alterations are specific, pathogenic, and somatically 
acquired. In addition, the majority of EBF1 and PAX5 deletions affect only these genes, 
thus conclusively identifying them as the target of the deletions. Moreover, the average 
number of deletions within an individual B-ALL case was 3.83, and focal amplifications 
were uncommon, suggesting global genomic instability is not an underlying mechanism. 
Lastly, although somatic point mutations were identified in PAX5, sequencing of EBF1 
and Ikaros failed to reveal any evidence of mutations, ruling out a high mutational rate.  
 
The most common targets of these genetic alterations (EBF1, PAX5, and Ikaros) 
play central roles in the development of normal B-cells.
56
 In mice the complete absence 
of Ebf1 or Pax5 results in the arrest of B-cell development at the early pro-B or pro-B-
cell stage,
54,55
  and loss of Ikaros leads to an arrest at an even earlier stage of lymphoid 
development.
67
 Moreover, haploinsufficiency of Ebf1 leads to a partial block in B cell 
development,
54
 a phenotype that is further accentuated in mice haploinsufficient for both 
Ebf1 and E2a.
68
 In addition, loss of Ikaros through the expression of a dominant negative 
Ikaros isoform predisposes mice to the development of T-lineage malignancies.
69
 
 
The overall consequence of the identified lesions is to reduce the level of the 
specific transcription factor either as a result of mono-allelic deletion or the generation of 
altered forms of the specific protein. Whether some mutations result in dominant negative 
forms of PAX5, or alternatively alter transcriptional activity in a promoter specific 
manner requires further investigation. It is important to note that during the normal 
development of B-cells, PAX5 is subjected to allele-specific regulation, with only a single 
PAX5 allele transcribed during the earliest phase of B-cell commitment and then a switch 
to bi-allelic expression as B-cells begin to differentiate.
70
 The loss of a wild-type PAX5 
allele from the identified mutations would eliminate the ability to turn on normal bi-
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allelic transcription, which may directly contribute to the differentiation arrest seen in 
ALL.  
 
Members of the PAX family of transcription factors including PAX3, PAX7, and 
PAX8 have previously been identified as targets of tumor-associated translocations
71
 that 
result in the over-expression of PAX fusion proteins. In addition, over-expression of 
wild-type PAX5 occurs as a result of its rearrangement into the IGH locus in non-
Hodgkin lymphoma.
72
 In sharp contrast to over-expression, however, our results 
implicate subtle changes in the dosage of PAX5 and other key regulators of B-cell 
development in the pathogenesis of ALL. Although heterozygous alterations of PAX5 
may have only subtle effects on their own, these effects are likely to contribute directly to 
leukemogenesis in combination with other oncogenic lesions. 
 
The identified high frequency of alterations of B-cell development genes in 
pediatric B-progenitor ALL represents a lower limit of the true frequency. Direct copy 
number analysis of those genes with low density SNP coverage along with full sequence 
analysis of all genes involved in controlling B-cell development and differentiation will 
be required to define the overall frequency. Nevertheless, our results demonstrate an 
unexpectedly high frequency with distinct patterns of mutations among the various 
genetic subtypes of pediatric ALL. Experiments to directly assess the effect of co-
expressing PAX5 mutants and fusion proteins such as ETV6-RUNX1 in murine models 
should provide valuable insights into the ability of these lesions to collaborate in 
leukemogenesis. Moreover, attempts to determine whether small molecule inducers of 
differentiation can bypass the block resulting from the identified lesions, and whether 
these molecules in turn would trigger a leukemia cell-specific apoptotic response, could 
lead to new therapeutic approaches for pediatric ALL. 
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CHAPTER 3 
Pax5 HAPLOINSUFFICIENCY COOPERATES WITH BCR-ABL1 TO INDUCE 
ACUTE LYMPHOBLASTIC LEUKEMIA

 
 
 
3.1 INTRODUCTION 
 
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy 
and is comprised of several distinct genetic subtypes including B-progenitor leukemia’s 
with t(9,22)[BCR-ABL1], t(1,19)[TCF3-PBX1], t(12,21)[ETV6-RUNX1], rearrangements 
of MLL, and hyperdiploid or hypodiploid karyotypes, and T-lineage leukemias.
1
 These 
defining genetic lesions play a role in disease initiation,
6
 but alone are insufficient to 
generate overt leukemia. In an effort to identify cooperating oncogenic lesions, we 
recently performed genome-wide copy number and loss-of-heterozygosity (LOH) 
analyses on over 400 pediatric ALL leukemias.
7
 These analyses identified somatic 
mutations in genes encoding regulators of B-cell development and differentiation in over 
40% of B-progenitor ALLs. The most common targets of these loss-of-function 
mutations were the transcription factors PAX5, IKZF1, and EBF1, with PAX5 being 
mutated in over 30% of patients. Notably, BCR-ABL1 ALL was characterized by a high 
frequency of mutations of IKZF1 (85%), PAX5 (55%), and CDKN2A/B (encoding 
INK4A/ARF and p15, 55%), suggesting that these lesions cooperate with BCR-ABL1 in 
lymphoid leukemogenesis.
19
  
 
The mutations of B cell development genes are hypothesized to contribute to 
leukemogenesis by inducing a block in the differentiation of the leukemic cells. 
Consistent with this hypothesis, the most frequent target of these mutations, the PAX5 
transcription factor, is essential for normal B cell differentiation with loss of the gene 
resulting in a complete arrest at an early pro-B cell stage of development in the bone 
marrow of Pax5-deficient mice.
16
 PAX5 normally functions by restricting the 
multilineage potential of early lymphoid progenitors to the B cell pathway by repressing 
lineage-inappropriate genes and activating B cell–specific genes such as CD79a, CD72, 
CD19, and BLNK.
15,73,74
 Moreover, continued expression of PAX5 is required for 
maintenance of cells to the B cell lineage. For example, conditional deletion of Pax5 in 
committed murine Pro-B cells results in their reversion to a multipotent state from which 
T lymphocytes and macrophages can be generated.
18
 Thus, PAX5 serves as a master 
regulator controlling the normal commitment and differentiation of hematopoietic 
progenitors to the B cell lineage.  
 
The genomic data, supporting a role for altered PAX5 expression in the 
pathogenesis of pediatric ALL, are diverse and include mono-allelic deletions of the 
entire gene, focal deletions leading to the expression of hypomorphic PAX5 isoforms, 
chromosomal translocations producing PAX5 fusion proteins, and PAX5 DNA sequence 
                                                 
 

 Adapted with permission. Miller C, Su X, Andersson A, Dang J, Mullighan C, Ma J, Zhang J, Wang M, 
Williams R, Downing J. Pax5 Haploinsufficiency Cooperates with the BCR-ABL1 Oncogene to Induce 
Acute Lymphoblastic Leukemia. Manuscript in preparation. 
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alterations that result in missense mutations of conserved residues in the DNA-binding 
domain, or nonsense, frame shift, or splice site mutations in the transcriptional regulatory 
domains.
7
 Despite these strong human genomic data, mice heterozygous for a Pax5 null 
allele show no significant immune system abnormalities and fail to develop B lineage 
leukemias during their lifetime.
16
 The absence of an overt phenotype within mice raises 
the possibility that the PAX5 alterations detected in pediatric ALL are bystander or 
passenger mutations, and are not mechanistically involved in the development or 
maintenance of the leukemic clone. To directly assess the contribution of a reduction in 
Pax5 expression to leukemogenesis, we assessed the susceptibility of Pax5
+/-
 mice to 
BCR-ABL1-induced lymphoid leukemia. Our data demonstrates that haploinsufficiency 
of Pax5 renders mice susceptible to the development of ALL, and directly cooperates 
with the loss of the tumor suppressor gene Arf in BCR-ABL1-induced lymphoid 
leukemogenesis. 
 
 
3.2 MATERIALS AND METHODS 
 
 
3.2.1 Mice 
 
Wild type, Pax5
+/-
, and Arf
+/-
, as well as intercrosses of these genotypes were 
maintained on a C57BL/6 background. All animal experiments were performed 
according to St. Jude Children’s Research Hospital Institutional Animal Care and Use 
Committee-approved protocols. 
 
 
3.2.2 Bone Marrow Transduction and Transplantation Analysis 
 
All bone marrow transplant experiments were performed as previously 
described.
75
 The Murine Stem Cell Virus (MSCV) retroviral expression construct 
containing the p185 isoform of BCR-ABL1 (MSCV-GFP-IRES-p185 was provided by O. 
Witte (University of California, Los Angeles). The p185 BCR-ABL1 cDNA cassette was 
removed from this virus and recloned into a variant version of this vector such that the 
BCR-ABL1 gene was cloned 3’ of the GFP gene with an internal ribosomal entry site 
(IRES) positioned between the cDNAs (MSCV-GFP-IRES-p185 BCR-ABL1). 
Replication-incompetent, ecotropic retrovirus was made by transient transfection of  
Phoenix-Eco packaging cells (G. Nolan, Stanford University, Stanford CA) using 
previously described methods. Bone marrow (BM) cells were harvested from Pax5
+/+
, 
Pax5
+/-
, Arf
+/-
, and Pax5
+/-
Arf
+/-
 mice and transduced in suspension for 3 hours with 
MSCV-GFP-IRES-p185 BCR-ABL1 retrovirus. Cells were washed and injected (2 x 10
6
 
per mouse) into lethally irradiated (11Gy in two doses) wild-type C57BL/6 recipient 
mice. Mice were observed daily for signs of disease and necropsies were performed on 
all moribund animals.  
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3.2.3 Histology 
 
Tissues were fixed in 10% buffered formalin, embedded in paraffin, and sections 
were stained with hematoxylin and eosin. Cytospins were prepared by centrifuging 1 x 
10
5
 BM cells onto a microscope slide using a Wescor cytocentrifuge 7620 (Logan, UT). 
Cytospins were stained with Wright’s stain. 
 
 
3.2.4 FACS Analysis and Cell Sorting 
 
All antibodies were obtained from BD Biosciences (San Jose, CA).  Flow 
cytometric analysis was performed using a BD LSR II (BD Biosciences) and the 
following antibodies:  B220-APC, CD43-biotin/SA-PE-Texas Red, CD19-APC-Cy7, 
BP1-PE, and IgM-PE-Cy7. Leukemias that were less than 80% GFP positive in the BM 
were subject to sorting for GFP positive cells using a FACSAria cell sorter (BD 
Biosciences). 
 
 
3.2.5 Genomic DNA Extraction and Southern Blot Analysis of Proviral Integrations 
 
Genomic DNA was isolated from leukemia cells by proteinase K digestion 
followed by phenol:chloroform:isoamylalcohol extraction and ethanol precipitation as 
previously described.  DNA was quantified using a NanoDrop spectrophotometer and its 
quality assessed using agarose gel electrophoresis. The number of proviral integrations in 
selected tumors was determined by Southern Blot Analysis. Briefly, 3 micrograms of 
genomic DNA was digested with HindIII, separated on a 0.7% agarose gel, and 
transferred to a Hybond N+ membrane (Amersham Biosciences). The membrane was 
hybridized with a 
32
P-radiolabeled 724bp NcoI/NotI DNA fragment DNA probe, 
corresponding to the GFP cDNA.  
 
 
3.2.6 Western Blotting 
 
Five million leukemias cells were washed with PBS and lysed with 4x LDS 
sample buffer (Invitrogen).  15ul of lysate was separated on NuPAGE 4-12% Bis-Tris 
gels, transferred to nitrocellulose membranes, and after blocking were incubated with 
either an N-terminal Pax5  antibody (Chemicon, now Millipore, Billerica, MA) or a p19 
Arf antibody (Abcam, Cambridge, MA). Following incubation with secondary 
antibodies, blots were developed using the SuperSignal West Femto Max Sensitivity 
Substrate chemiluminescent reagent (Pierce, Rockford, IL), and images were captured 
using the ChemiDoc XRS gel imaging system (Bio-Rad Laboratories, Hercules, CA). 
Membranes were subsequently stripped, blocked and reprobed with a C-terminal Actin 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) as a loading control. 
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3.2.7 Array-based Comparative Genomic Hybridization 
 
The Agilent (Santa Clara, CA, USA) eArray 5.0 
(https://earray.chem.agilent.com/earray/) platform was used to design microarrays for 
CGH analysis. Two separate arrays were designed: For the first array, we used Agilent’s 
Mouse Genome CGH Microarray 244A and removed all probes located to chromosomes 
X and Y. The vacated space was filled in with 17,573 custom 60-mer oligonucleotide 
probes that covered at a 250 bp resolution, twenty genes that are the most frequent targets 
of CNAs in human BCR-ABL1 ALL. The coverage of these 20 genes included 100kb 
upstream and downstream of their annotated exons. For the second array, we 
incorporated 238,382 60-mer oligonucleotide features from across the mouse genome 
(excluding features chromosomes X and Y) along with an additiona 5,099 control 
features selected from the eArray library. The combination of 476,623 features provides a 
median feature spacing of 4,453 bp (the number of features and median spacing for each 
individual chromosome are listed in Supplementary Table 8). The arrays were printed 
using the Agilent Sureprint technology using in situ oligonucleotide synthesis. 
 
 
3.2.8 Quantitative Genomic Real-time PCR 
 
Confirmation of copy number abnormalities using genomic quantitative real-time 
PCR (gqPCR) was performed for Pax5, Cdkn2a/b, Ikzf3, Ebf1, Zfp456, and V1rf2. 
 
 
3.2.9 Genomic Resequencing of Pax5 
 
Genomic resequencing of all the coding exons of Pax5 was performed on the 50 
leukemia samples analyzed by array CGH. Genomic DNA was extracted as previously 
described and each exon was PCR amplified using 1U of AccuPrime GC-Rich DNA 
polymerase (Invitrogen, Carlsbad, CA), and 0.2µM forward and reverse primers. Primer 
sequences are available upon request. PCR products were purified and then sequenced 
directly using Big Dye Terminator (v3.1) chemistry on a 3730xl DNA Analyzers 
(Applied Biosystems, Foster City, CA). Mutations detected by direct sequencing were 
validated by cloning PCR products in pGEM-T easy (Promega, Madison, WI) and 
multiple clones sequenced in both directions with M13 primers. 
 
 
3.2.10 Structural Modeling of Pax5 Mutations 
 
A structural view of the PAX5 paired domain was generated by PyMOL v0.99 
(http://pymol.sourceforge.net/) using the coordinates of the X-ray structure of PAX5 
interacting with ETS1 on DNA, and PAX6 deposited with the Brookhaven Data Bank 
(PDB: 1K78 and 6pax; http://www.rcsb.org/pdb/).
41,42
 The protein sequences of the 
paired domains of PAX6 and PAX5 are 70.1% identical. 
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3.2.11 Gene Expression Profiling 
 
RNA was extracted as previously described
76
 from the leukemic bone marrow of 
10 Pax5
+/+
, 5 Pax5
+/-
 mice, as well as 5 Pax5
+/- 
mice that later lost their second Pax5 
allele. Additionally, all leukemias with a bone marrow % GFP less than 80% were flow 
sorted to enrich the sample to greater than 95% GFP positive cells. In addition, RNA was 
extracted from flow sorted normal hematopoietic cell subpopulations representing Hardy 
fractions A-F (at least 5 individual animals were used as biological replicates for each 
fraction) from the bone marrow of Pax5
+/+
 and Pax5
+/-
 mice. Flow sorted cells from 
Hardy fractions A and B were also obtained from Pax5
-/-
 mice (5 samples from each 
fraction). The antibodies and sorting strategy used are outlined in detail in a previous 
methods section. The quality of the RNA was assessed using the Agilent Bioanalyzer 
(Agilent, Santa Clara, CA). Samples were hybridized to Affymetrix 430v2.0 microarrays 
(Affymetrix, Santa Clara, CA) as previously described.
77
 
 
Probe intensities were generated using the MAS 5.0 algorithm, probe sets called 
absent in all samples were excluded, and expression data was log-transformed. To define 
the gene expression signature of mouse BCR-ABL1, we used Limma (Linear Models for 
Microarray Analysis)
78
, the empirical Bayes t-test implemented in Bioconductor
79
 and the 
Benjamini-Hochberg method of false discovery rate (FDR) estimation
80
 to identify probe 
sets differentially expressed between mouse BCR-ABL1 and normal B-cells. 
  
 Principal component analyses were performed using Gene Expression Explorer 
v1.1 (Qlucore AB, Lund, Sweden). In addition to conventional PCA analyses, this 
program enables PCA to be performed on a selected set of samples (in our case Hardy 
fractions A-F) and then applying these principal components on another set of samples 
(in our case the leukemias), without letting the second set of samples contribute to the 
calculation of the three principal components. This allows diverse samples to be analyzed 
together and provides a powerful tool for investigating similarities between normal and 
malignant cells that cannot be revealed otherwise.
81
 
  
 
3.2.12 Gene Set Enrichment Analysis 
 
To search for enrichment of specific transcriptional programs in the various 
normal Hardy fractions and leukemias, gene set enrichment analyses
53
 were performed. 
Gene sets of the top up- and down-regulated genes in the signatures of mouse BCR-ABL1 
and Core ESC-like Module were created and added to the collection of currated gene sets 
available at the Molecular Signatures Database (http://www.broad.mit.edu/gsea/msigdb/). 
GSEA of mouse leukemia and human BCR-ABL1 were then performed using this 
expanded collection of gene sets. GSEA then determines if the members of a gene set 
(here a Core ESC-like Module) are randomly distributed in the ranked gene list, or 
primarily found at the top or bottom. Occurrences of members of the gene set in the 
ranked gene list are shown as vertical black lines above the ranked signature. An 
enrichment score (ES) is calculated that reflects the degree to which a gene set is 
overrepresented at the top or bottom of the entire ranked list. The ES is a running sum, 
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Kolmogorov-Smirnov like statistic calculated by walking down list L and increasing the 
statistic when a gene in S is encountered, and decreasing it when it is not. The magnitude 
of the increment depends on the strength of association with phenotype, and the ES is the 
maximum deviation from zero encountered in the random walk, and is depicted as a red 
curve. The "leading edge" genes are those members of the gene set responsible for the 
observed enrichment, and are those hits occurring to the left of the vertical dotted red 
line. The significance level of ES is calculated by phenotype-based permutation testing, 
and when a database of gene sets are evaluated, as in this analysis, the significance level 
is adjusted for multiple hypothesis testing by calculation of a false discovery rate (FDR). 
 
 
3.3 RESULTS 
 
 
3.3.1 Haploinsufficiency of Pax5 Renders Mice Susceptible to B-ALL 
 
Mice hemizygous for a Pax5 null allele (Pax5
+/-
) have normal adult B cell 
development and fail to spontaneously develop leukemia. To directly assess whether the 
loss of one allele of Pax5 can cooperate with a known oncogenic lesion in B cell 
transformation, we directly assessed the ability of Pax5 haploinsufficiency to cooperate 
with the expression of the t(9;22) encoded BCR-ABL1 oncogene, a combination of 
lesions that is detected in greater than 50% of pediatric BCR-ABL1 ALL cases. Bone 
marrow cells from untreated wild-type (Pax5
+/+
) or Pax5
+/-
 mice were transduced with a 
MSCV-GFP-IRES-BCR-ABL1 (p185) retrovirus designed to express a low level of the 
BCR-ABL1 oncogene from an internal ribosomal entry site. Two million unsorted 
transduced cells were transplanted after minimal ex vivo manipulation into cohorts of 
lethally irradiated C57BL/6J recipient mice (Figure 3-1A). Expression of BCR-ABL1 in 
bone marrow cells from wild type mice induced a pre-B cell lymphoblastic leukemia 
(B220
+
, CD43
+
, CD19
+
 and BP1
+
) in recipient animals with a median survival of 60 days 
post transplant (Figures 3-1B-C; Figure 3-2A). By contrast, mice transplanted with BCR-
ABL1 expressing Pax5
+/-
 cells developed leukemia with significantly decreased latency 
(median survival of 36 days) and increased penetrance (Figure 3-1B). Interestingly, the 
leukemias that developed from Pax5
+/- 
cells had a more immature B progenitor 
phenotype, with the majority containing a mixture of Pre-B cells and Pro-B cells 
characterized by reduced or absent BP1 expression (Figure 3-2B; Figure 3-3). Moreover, 
19% of the BCR-ABL1 Pax5
+/-
 leukemias had a very immature Pre-Pro-B cell phenotype 
(B220
+
, CD43
+
, CD19
-
, BP1
-
) (Figure 3-2C; Figure 3-3), a phenotype that was observed 
in only a rare BCR-ABL1 Pax5
+/+
 leukemia.  
 
The primary leukemias that developed from Pax5
+/+
 and Pax5
+/-
 cells were 
transplantable into sublethally irradiated secondary recipients and resulted in the rapid 
development of overt leukemia with a phenotype identical to that seen in the donors. 
Southern blot analysis to assess the clonality of retroviral integrations revealed the vast 
majority of both the Pax5
+/+
 and Pax5
+/-
 leukemias to be monoclonal, irrespective of 
their relative stage of B cell differentiation (Figure 3-2D; Figure 3-4; Table 3-1).
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Figure 3-1 Pax5 haploinsufficiency cooperates with BCR-ABL1 to induce ALL  
 
A, Structure of the retroviral vector used to transduce bone marrow and a schematic 
representation of the transduction protocol. Briefly, Pax5
+/+
 and Pax5
+/-
 bone marrow 
was harvested and transduced with the MSCV-GFP-IRES-BCR-ABL1 retroviruses and 
transplanted into lethally irradiated C57BL/6J animals. B, Kaplan-Meier survival curves 
from a representative experiment of mice transplanted with MSCV-GFP-IRES-BCR-
ABL1 transduced Pax5
+/+
 or Pax5
+/-
 bone marrow. Leukemias developed in the Pax5
+/-
 
mice with a decreased latency when compared to Pax5
+/+
 tumors P=0.0003 (Breslow-
Gehan-Wilcoxon test). Similar results were observed in 4 independent retroviral 
transductions and transplantations experiments with between 10 and 20 mice per group. 
C-D, Bone marrow from Pax5
+/+
 (C) and Pax5
+/-
 (D) tumors, stained with Hematoxylin-
Eosin. Insets, cytospins of bone marrow stained with Wright Giemsa stain.
 37 
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Figure 3-2 Immunophenotype and clonality analysis of BCR-ABL1 induced 
leukemias 
 
A, Representative FACS analysis of BCR-ABL1/Pax5
+/+
 leukemias using antibodies 
against B220, CD43, CD19, and BP1. B, Representative FACS analysis demonstrating 
the predominant immunophenotype seen in the BCR-ABL1/Pax5
+/-
 leukemias. C, 
Representative FACS analysis of the immature pre-pro-B cell leukemias identified in 
19% of the BCR-ABL1/Pax5
+/-
 leukemias. D, Southern blot analysis of HindIII digested 
genomic DNA from Pax5
+/+
and Pax5
+/-
 leukemias hybridized with a 724bp GFP probe.
 39 
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Figure 3-3 Leukemia immunophenotypes  
 
A, Schematic representation of the pathway followed for flow analysis of Pax5 tumors. A 
live cell gate was drawn using Forward Scatter-Area (FSC-A) and DAPI. A gate was 
drawn around single cells.  Only cells that are GFP positive are analyzed by creating a 
GFP gate. B, Pax5
+/+
, Pax5
+/-
, p19Arf
+/-
, and Pax5
+/-
p19Arf
+/-
 representative tumors are 
shown revealing the various immunophenotypes identified in each of the tumor groups.
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Figure 3-4 Assessment of leukemia clonality 
 
Southern Blot Analysis of 3 independent experiments is represented. These blots reveal 
that Pax5
+/+
 and Pax5
+/-
 tumors are monoclonal while p19Arf
+/-
 and Pax5
+/-
p19Arf
+/-
 
tumors are oligoclonal. C=control.
 42 
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Table 3-1 Clonality analysis of BCR-ABL1-induced leukemias 
 
Leukemia genotype (N) Mono
* 
Oligo
† 
 
Pax5
+/+
 (7) 7 0  
Pax5
+/- 
(14) 12 2  
Arf
+/- 
(17) 5 12  
Pax5
+/-
Arf
+/- 
(7) 0 7  
 
*
Mono signifies one band by Southern blotting of genomic from bone marrow cells that 
were either ≥90% GFP+ or if less than 90% was sorted for GFP+ cells;  
†
Oligo signifies ≥2 bands by Southern blot analysis. 
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 To ensure that the increased susceptibility of Pax5
+/-
 mice to leukemia was not 
restricted to BCR-ABL1-induced disease, a cohort of young Pax5
+/+
 (N=20) and Pax5
+/-
 
(N=25) mice were thymectomized and then treated with a single 100mg/kg dose of the 
alkylating agent N-ethyl-S-nitrosourea (ENU). Pax5
+/-
 mice exhibited a markedly 
increased frequency of ALL in comparison to wild type animals with 24 of 25 Pax5
+/-
 
animals succumbing to leukemia (median latency 246 days), compared to only 3 of 20 
Pax5
+/+
 animals (P<0.0001, Figure 3-5). Furthermore, 20 of 22 evaluable Pax5
+/-
 tumors 
were of B-progenitor cell lineage, in contrast to the Pax5
+/+
 leukemias which were either 
myeloid (N=2) or T-lymphoid (N=1). Taken together these data demonstrate that 
haploinsufficiency of Pax5 results in an increased susceptibility to the development of B 
progenitor acute lymphoblastic leukemia. 
 
 
3.3.2 Mono-allelic Loss of Pax5 Cooperates with Arf Loss in BCR-ABL1  
Induced ALL 
 
 In addition to PAX5 deletions, human BCR-ABL1 ALLs frequently harbor a 
deletion of INK4A/ARF (CDKN2A), with over 20% of cases containing deletions of both 
genes. Expression of BCR-ABL1 in primary murine pre-B cells induces the Arf 
checkpoint and triggers an apoptotic response; thus, loss of Arf directly enhances the 
oncogenicity of BCR-ABL1 to induce ALL in mice. To assess whether mono-allelic 
deletions of Pax5 can cooperate with Arf loss in BCR-ABL1 induced leukemia, bone 
marrow cells from mice heterozygous for null alleles of Pax5, Arf, or both genes were 
transduced with MSCV-GFP-IRES-BCR-ABL1 and transplanted into recipient animals. 
As shown in Figure 3-6, mice transplanted with BCR-ABL1 transduced Pax5
+/-
 or Arf
+/-
 
cells developed leukemias with a reduced latency when compared to wild type cells. No 
significant difference was observed in the latency of disease onset between Pax5
+/-
 and 
Arf
+/-
 cells. Transduction of bone marrow cells from compound heterozygous mice 
(Pax5
+/-
 Arf
+/-
) followed by transplantation into recipient mice resulted in a further 
decrease in disease latency over that observed with wild type or single mutant cells 
(Figure 3-6), thus demonstrating a direct cooperativity of these two lesions in the 
development of BCR-ABL1-induced leukemia. Importantly, the immunophenotype of the 
BCR-ABL1-induced leukemias were primarily dictated by the Pax5 gene status, with a 
shift toward a more immature B cell phenotype with the loss of one Pax5 allele (Figure 3-
3). Interestingly, in contrast to the clonal leukemias that developed in wild type or Pax5
+/-
 
mice, Southern blot analysis of the Arf
+/-
 leukemias revealed the majority to be 
oligoclonal in nature (Figure 3-6; Figure 3-4). 
 
 
3.3.3 Mutations of Pax5 and Ink4a/Arf are Spontaneously Selected For during 
Leukemogenesis 
 
 Our data demonstrate that mono-allelic loss of Pax5 not only cooperates with 
BCR-ABL1 in leukemogenesis, but further enhance the known cooperativity of Arf loss. 
These data raise the possibility that BCR-ABL1-induced leukemias may spontaneously 
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Figure 3-5 Kaplan-Meier survival curves of mice treated with ENU 
 
Kaplan-Meier survival curve of mice that were injected with one dose of 100mg/kg ENU 
(N-ethyl-S-nitrosourea).  Twenty four of twenty five Pax5
+/-
 animals succumbed to 
disease with a median survival of 246 days while only three of twenty Pax5
+/+
 animals 
developed leukemia (P<0.001). These data suggest that Pax5 haploinsufficiency 
cooperates during leukemogenesis in multiple animal models. 
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Figure 3-6 Pax5 and Ink4a/Arf haploinsufficiency cooperate with BCR-ABL1 to 
induce ALL 
 
A, Kaplan-Meier plot showing survival of mice transplanted with MSCV-GFP-IRES-
BCR-ABL1 transduced Pax5
+/+
, Pax5
+/-
, Arf
+/-
 or Pax5
+/- 
Arf
+/-
 bone marrow cells 
(p<0.0001). Pax5
+/-
 and Arf
+/-
 leukemias develop with a decreased latency when 
compared to Pax5
+/+
 leukemias, p = 0.01 and p < 0.001, respectively. Pax5
+/-
 and Arf
+/-
 
tumors develop with no significant change in latency when compared to each other p = 
0.077. Pax5
+/- 
Arf
+/-
 tumors develop with a decreased latency when compared to Pax5
+/-
 
or Arf
+/-
 tumors p = 0.007 and p = 0.0045, respectively. All p values calculated using 
Breslow-Geahn-Wilcoxon test. N=10 in all experimental arms. B, Southern Blot Analysis 
of HindIII digested genomic DNA from
 
Arf
+/-
 and Pax5
+/- 
Arf
+/-
 leukemias hybridized 
with a 724bp GFP probe.
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select for mutations in these genes. Further supporting this possibility was the occurrence 
of a Pre-Pro-B cell immunophenotype in a subset of Pax5
+/-
 leukemias, and in rare wild 
type and Arf
+/-
 cases, suggesting that this immature phenotype may results from 
additional lesions in B cell development genes. To explore these hypotheses, we 
performed array-based comparative genomic hybridization (aCGH) on 50 BCR-ABL1-
induced leukemias (15 Pax5
+/+
, 25 Pax5
+/-
, and 10 Arf
+/-
) to identify regions of copy 
number alterations (CNAs). For this analysis we used Agilent (Santa Clara, CA, USA) 
murine oligonucleotide microarrays containing over 450,000 probes with a resolution 
across the genome of approximately 4.5kb. To further enhance the resolution of this 
platform, we customized the arrays by tiling at a 250 bp resolution through the 20 genes 
that are most commonly mutated by CNAs in human BCR-ABL1 ALL. Included in this 
list of genes are Ink4a/Arf, Pax5, Ebf1, and the Ikaros gene family Ikzf1, Ikzf2 and Ikzf3. 
We also sequenced all coding exons of Pax5 in the leukemia cells from this cohort.  
  
 The aCGH data revealed a surprisingly low number of CNAs/leukemia with a 
mean of only 0.96 CNAs/case (range 0-5), with losses (0.62, range 0-3) twice as common 
as gains (0.34, range 0.3) (Table 3-2). The frequency of CNAs differed across the various 
genotypes, with a mean of 1.73 CNAs/leukemia (range 0-5) in wild type mice compared 
to only 0.60 and 0.70 in Pax5
+/-
 and Arf
+/-
 leukemias, respectively. Despite the paucity of 
CNAs, a recurrent gain of chromosome 5 or 5q was identified in 7/15 BCR-ABL Pax5
+/+
 
and 1/10 BCR-ABL1 Arf
+/-
 leukemias, but never in BCR-ABL1 Pax5
+/-
 leukemias (Figure 
3-7A). In addition, a number of other recurrent lesions were identified, with the most 
common abnormalities targeting Pax5, Ikzf3, and Ink4a/Arf (Figure 3-7; Figure 3-8; 
Table 3-3). 
  
 Three leukemias (2 Pax5
+/+
 and 1 Pax5
+/-
) had focal deletions targeting the 
Ink4a/Arf Ink4b locus, including a bi-allelic deletion in one of the Pax5
+/+
 leukemias that 
included the entire Ink4a/Arf Ink4b locus (Figure 3-7B-C). The second Pax5
+/+
 leukemia 
had a deletion that included the common exon of the Ink4a locus, exon 2, but did not 
include Ink4b (Figure 3-7B-C). The Pax5
+/-
 leukemia had a deletion that extended from 
exon 1β through the end of Ink4b (Figure 3-7B-C).  Taken together, the common region 
of deletion in the three leukemias was Arf, thereby definitively identifying Arf as the 
target of the mutations. Thus, loss of Ink4a/Arf is spontaneously selected for in BCR-
ABL1-induced leukemia. To assess whether Arf was inactivated in the absence of 
genomic alterations, we performed western blot analysis on protein lysates from a subset 
of the leukemias and observed only a rare leukemia (two Pax5
+/-
) with markedly reduced 
expression of p19
ARF 
consistent with silencing. By contrast, expression of p19
Arf
 was 
detected in Arf
+/-
 leukemias, consistent with haploinsufficiency.  
  
 The most common targets of CNAs in the murine leukemias were genes involved 
in normal B cell development including Pax5, Ebf1, and Ikzf3 (Figure 3-8; Figure 3-9; 
Table 3-3). In addition 4 leukemias were found to have point mutations of Pax5 effecting 
conserved residues in the paired DNA-binding domain, or resulting in a frame-shift 
mutation in the transcriptional regulatory domain (Figure 3-10; Table 3-4). Collectively, 
mutations targeting these genes were identified in 30% of analyzed leukemias that arose 
from Pax5
+/+
 or Arf
+/-
 cells. Even more surprising was the identification of a high 
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Table 3-2 Mean number of CNA in murine leukemias 
 
Subtype N 
Gains 
(range) 
Losses 
(range) 
Total 
(range) 
Pax5
+/+
 15 0.93 (0-3) 0.80 (0-3) 1.73 (0-5) 
Pax5
+/-
 25 0.04 (0-1) 0.56 (0-1) 0.60 (0-2) 
Arf
+/-
 10 0.20 (0-1) 0.50 (0-2) 0.70 (0-2) 
All cases 50 0.34 (0-3) 0.62 (0-3) 0.96 (0-5) 
 
 
 
 
 
Figure 3-7 Detection of recurrent CNAs in murine BCR-ABL1 leukemias 
 
A, Heatmap of log2 ratio of array CGH copy number data (median smoothed with a 
window of five markers) for 50 murine BCR-ABL1 leukemias. The leukemias are 
grouped according to their genotype (Pax5
+/+
, Pax5
+/-
, and Arf
+/-
) and the probes are 
group by chromosomes as listed on the left. Blue depicts regions of loss and red regions 
of gain with the relative scale shown in the lower right. B, Heatmap of log2 ratio of array 
CGH copy number data of the region on chromosome 4 that contains Ink4a/Arf and Ink4b 
for 3 BCR-ABL1 leukemias that have acquired CNAs involving this locus. C, Genomic 
map of the Ink4a/Arf and Ink4b locus showing the location of the CGH oligonucleotide 
probes (blue lines at the top) and the position of the individual genes contained within 
this genomic region (bottom). * indicates a gap in the UCSC genome build. The log2 copy 
number data for the three BCR-ABL1 leukemias are depicted. The red arrows indicate the 
genomic location of exons analyzed by quantitative PCR for copy number validation. 
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Figure 3-8 Pax5 is a common target of copy number alterations 
 
A, Heatmap of log2 ratio of array CGH copy number data of the region on chromosome 4 
that contains Pax5 for 2 BCR-ABL1 Pax5
+/-
 leukemias that have acquired deletions of the 
non-targeted, wild type Pax5 allele. B, Genomic map of the Pax5 locus showing the 
location of the CGH oligonucleotide probes (blue lines at the top) and the position of the 
gene contained within this genomic region (Bottom). The log2 ratio data for two BCR-
ABL1 leukemias are depicted. The red arrows indicate the genomic location of the exons 
analyzed by quantitative PCR for copy number validation. C, Heatmap of log2 ratio of 
array CGH copy number data of the region containing Pax5 exon 2 (represented by a 
single probe within this region). Pax5 exon 2 was deleted in the targeted Pax5 null allele. 
A deletion involving the single exon 2 probe was detected in 7 Pax5
+/-
 leukemias, 
suggesting gene conversion leading to bi-allelic targeted alleles. D, Genotyping PCR 
confirmed loss of the wild type allele in leukemias that had deleted the exon 2 probe 
(designated by an *). Western blot analysis also demonstrated an absence of Pax5 protein 
expression in these leukemias. WT, wild type band; KO, knock out band. 
 
 52 
 53 
Table 3-3 Recurring CNA (rank ordered by frequency) 
 
Genes 
Loss/ 
Gain 
Pax5
+/+
 
N=15 
Pax5
+/- ‡ 
N=25 
Arf
+/-
 
N=10 
# total 
lesions 
Pax5* Loss† 2 (13%) 9 (36%) 1 (10%) 12 
Ikzf3 Both 3 (20%) 3 (12%) 3 (30%) 10 
+5 Gain 7 (47%) 0 1 (10%) 8 
Ink4a/Arf  Ink4b Loss 2 (13%) 1 (4%) 0 3 
+12 Gain 1 (7%) 0 1 (10%) 2 
+18 Gain 2 (13%) 0 0 2 
 
*Includes loss of heterozygosity (LOH) in 7 Pax5
+/-
 leukemias.  
†Eleven of twelve CNA were deletions while one was amplification. 
‡Pax5+/- leukemias reveal a significant increase in acquired Pax5 lesions, however, the 
cohort has been biased by the selection of leukemias that harbor an immature 
immunophenotype. 
 
 
 
 
 
 
Figure 3-9 Ikzf3 copy number analysis 
  
A, Log2 ratio aCGH copy number data of chromosome 11 flanking Ikzf3 exon 2 for 12 
representative leukemias (9 with CNA and 3 without) showing deletion or amplification 
of Ikzf3 exon 2. B, Coverage of the Ikzf3 locus for four of the leukemias shown in A.  
Each vertical line represents the genomic position and log ratio of an individual marker. 
A Red arrow indicates the genomic location of a quantitative PCR assay. 
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Figure 3-10 Pax5 point mutations 
 
A, Schematic of the functional domains of Pax5 showing the location of missense (▼) 
and frameshift (♦) mutations detected in this study. The mutations in red correspond to 
the most frequent Pax5 mutation detected in human pediatric ALLs. PD, paired domain, 
O, octapeptide domain, H, homeodomain, TD, transactivating domain, A, activating, I, 
inhibitory. B, Structural modeling of the position of the Pax5 paired domain mutations 
and their relationship to DNA-binding and Ets protein interaction. The DNA double helix 
is blue, the paired Pax5 DNA binding domain is yellow, and ETS-1, which binds to Pax5 
resulting in an increase in the latter’s DNA-binding activity, is green. Pax5 mutations that 
have been previously identified in human pediatric ALL are shown in red. Each mutation 
is predicted to either disrupt DNA-binding or alter the transcriptional regulatory domains 
of the protein. 
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Table 3-4 Mutation analysis (including CNAs and re-sequencing of Pax5) 
 
ID Genotype IP* Pax5 Mutation† Other CNA 
100 Pax5
+/+
 Pre-B 
  102 Pax5
+/+
 Pre-B 
  116 Pax5
+/+
 Pre-pro B homo G85R 
 120 Pax5
+/+
 Pre-B 
 
Arf deln 
124 Pax5
+/+
 Pre-B 
 
Ebf1 Δ6-7/+5 
128 Pax5
+/+
 Pre-B 
  228 Pax5
+/+
 Pre-B 
  136 Pax5
+/+
 Pre-B intron 5 deln Arf deln/Ikzf3 deln/+5 
140 Pax5
+/+
 Pre-B 
 
+5 
144 Pax5
+/+
 Pre-B 
 
+5 
148 Pax5
+/+
 Pre-B intron 5 amp Ikzf3 amp 
152 Pax5
+/+
 Pre-B 
  156 Pax5
+/+
 Pre-B 
 
+5/+18 
188 Pax5
+/+
 Pre-B 
 
+12 
192 Pax5
+/+
 Pre-B 
 
Ikzf3 deln/+5 
176 Pax5
+/-
 Pre-B 
  184 Pax5
+/-
 Pre-B 
 
Arf deln 
172 Pax5
+/-
 Pro-B P321fs 
 180 Pax5
+/-
 Pro-B P80R 
 230 Pax5
+/-
 Mixed Pre-B/Pro-B 
 
Ikzf3 deln 
234 Pax5
+/-
 Mixed Pre-B/Pro-B 
 
Ikzf3 deln 
238 Pax5
+/-
 Mixed Pre-B/Pro-B 
  242 Pax5
+/-
 Mixed Pre-B/Pro-B 
  246 Pax5
+/-
 Mixed Pre-B/Pro-B 
  250 Pax5
+/-
 Mixed Pre-B/Pro-B 
  254 Pax5
+/-
 Mixed Pre-B/Pro-B 
  258 Pax5
+/-
 Mixed Pre-B/Pro-B 
 
Ikzf3 deln 
262 Pax5
+/-
 Mixed Pre-B/Pro-B 
  266 Pax5
+/-
 Mixed Pre-B/Pro-B 
  104 Pax5
+/-
 Pre-pro B LOH 
 106 Pax5
+/-
 Pre-pro B LOH 
 160 Pax5
+/-
 Pre-pro B LOH 
 164 Pax5
+/-
 Pre-pro B LOH 
 168 Pax5
+/-
 Pre-pro B LOH 
 196 Pax5
+/-
 Pre-pro B LOH 
 200 Pax5
+/-
 Pre-pro B R38H 
 204 Pax5
+/-
 Pre-pro B Δ1-6 
 208 Pax5
+/-
 Pre-pro B Δ1-8 
 212 
216 
Pax5
+/-
 
Pax5
+/-
 
Pre-pro B 
Pre-pro B LOH 
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Table 3-4 continued 
 
  ID Genotype IP* Pax5 Mutation† Other CNA 
270 Arf
+/-
 Pre-B 
 
+12 
274 Arf
+/-
 Pre-B 
  278 Arf
+/-
 Pre-B 
  282 Arf
+/-
 Pre-B 
  286 Arf
+/-
 Pre-B intron 5 deln Ikzf3 deln 
290 Arf
+/-
 Pre-B 
  294 Arf
+/-
 Pre-B 
 
Ikzf3 deln 
298 Arf
+/-
 Pre-B 
  302 Arf
+/-
 Pre-B 
  306 Arf
+/-
 Pre-B 
 
Ikzf3 deln 
 
*IP, immunophenotype; LOH, loss of heterozygosity; Δ, deletion  
†Pax5 mutations include deletions, amplification, LOH, and sequence mutations
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frequency of mutations (CNAs and point mutations) in the non-targeted Pax5 allele in 
BCR-ABL1 Pax5
+/-
 leukemias. Specifically, two Pax5
+/-
 leukemias had focal deletions 
affecting a subset of the Pax5 coding exons, three had Pax5 point mutations, and 7 had 
undergone a gene conversion (copy neutral loss-of-heterozygosity) event leading to loss 
of the wild type allele, duplication of the targeted Pax5 null allele, and an absence of 
Pax5 expression (Figure 3-8C-D; Table 3-4). Thirteen of the Pax5
+/-
 leukemias were 
selected for genomic analysis because of a very immature Pro-B or Pre-Pro-B 
immunophenotype. Remarkably, 12 of these 13 leukemias had mutations of the wild type 
Pax5 allele. In addition, a single leukemia that arose in Pax5
+/+
 cells had a very immature 
Pre-Pro-B cell immunophenotype and was found to have a homozygous G85R Pax5 
DNA-binding domain mutation (Figure 3-10; Table 3-4). Thus, spontaneous inactivation 
of the wild type Pax5 allele is selected for at a relatively high frequency and correlates 
with a more immature phenotype. Taken together these data demonstrate a strong 
selective pressure for the acquisition of loss of function mutations in genes that regulate 
the normal transcriptional cascade required for early B cell differentiation. 
 
 
3.3.4 Gene Expression Analysis Reveals Similarities between the Leukemias and 
Their Normal Counterparts 
 
Due to the importance of Pax5 during normal B-cell development, gene 
expression profiling of flow sorted cells from distinct stages of B-cell development i.e., 
Hardy fractions A-F from Pax5
+/+
 and Pax5
+/-
 mice were performed. In addition, to 
investigate the effect of complete loss of Pax5 on the gene expression pattern during 
early B-cell development, cells from Hardy fraction A and B, were flow sorted from 
Pax5
-/- 
mice. In our first analysis, we used principal component analysis (PCA) and 
multi-group comparison to explore the gene expression changes that occur during normal 
development. This analysis revealed that cells from the different Hardy Fractions have 
distinct gene expression patterns (q =7.2 x 10
-19
) and the PCA accurately captures the 
temporal changes that occur during normal differentiation (Figure 3-11A). This analysis 
also showed that subtle gene expression changes occur with regard to a heterozygous loss 
of Pax5. In Hardy fraction A, no difference in the gene expression pattern could be 
detected with PCA or other supervised methods in bone marrow cells obtained from 
Pax5
+/+
, Pax5
+/-
, or Pax5
-/- 
mice. As expected, in Hardy fraction B, both PCA and 
supervised analyses revealed that BM from Pax5
-/-
 mice has a distinct gene expression 
profile. However, the difference that could be seen between Pax5
+/+ 
and Pax5
+/-
 cells was 
very subtle using this algorithm. 
 
Next, we investigated the relationship between normal flow sorted B-cells and the 
leukemias from Pax5
+/+
, Pax5
+/-
, and Pax5
+/-
 mice that later lost their second Pax5 allele. 
PCA showed that all leukemias, irrespective of their Pax5 status, were distinct from their 
normal counterparts (Figure 3-11B). To investigate if the leukemias shared more subtle 
transcriptional programs with any of the normal Hardy fractions, we applied PCA 
obtained from the normal cells only (Figure 3-11) on the leukemias. In this analysis, the 
leukemias do not contribute to the principal components, allowing us to investigate the 
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Figure 3-11 Gene expression analysis 
 
A, Principal Component Analysis of Hardy fraction development on Hardy stages A-F.  
All three Pax5 genotypes are included. L, leukemias; L-/-, Pax5
-/-
 leukemias; B-/-, Pax5
-/-
 
Hardy fraction B. B, PCA of Hardy fractions and Pax5 leukemias reveals that leukemias 
harbor a gene expression profile that is unique when compared to normal B-cells. C, The 
PCA analysis from part A was locked and the leukemias were overlaid in order to 
determine which Hardy stage of B-cell development the leukemias most closely 
resemble. This analysis revealed that the Pax5
+/+
 leukemias most closely resemble Hardy 
fraction C. The leukemias that have lost one Pax5 allele are most similar to Hardy 
fraction B, while the leukemias that have lost both functional Pax5 alleles, L-/-, most 
closely resemble Hardy fraction B cells from Pax5
-/- 
animals, depicted here as B-/-. D, 
The top 100 genes that define Hardy Fractions A through F are represented along with 20 
mouse leukemias (10 Pax5
+/+
 and 5 Pax5
+/-
 and 5 Pax5
+/-
 that have undergone LOH and 
are effectively Pax5
-/-
).  These gene expression profiles reveal that the Pax5 leukemias 
harbor gene expression profiles that are relatively immature; sharing the most similarity 
with the gene expression profile of Hardy fractions B and C. E, Gene expression analysis 
assessing changes that occur in Hardy fraction B when Pax5 is lost. Pax5
-/-
 Hardy 
fraction B cells harbor a completely dysregulated gene expression profile when compared 
to wild-type Hardy fraction B cells.  Several dysregulated Pax5 targets are included in the 
top 100 genes that define Hardy fraction B, including Rag2, Lef1, and CD19.
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similarities between the normal and the malignant cells (Figure 3-11C). This analysis 
showed that most of the leukemias shared transcriptional programs with Hardy fraction B 
cells. Interestingly, as can clearly be seen in Figure 3-11C, leukemias developed in 
Pax5
+/-
 mice that, as demonstrated by ArrayCGH had lost their other Pax5 allele, 
clustered close to the Hardy fraction B cells from Pax5
-/-
 mice. In addition, several of the 
leukemias that developed in Pax5
+/+
 mice shared transcriptional programs with Hardy 
fraction C cells suggesting that loss of one Pax5 allele is enough to impair leukemia 
development past Hardy fraction B. 
  
 To further explore the similarities between normal B-cells and the leukemias, the 
top 100 uniquely expressed genes in Hardy fractions A-F were extracted and investigated 
in the murine leukemias (Figure 3-11D). This analysis showed, as above, that the 
leukemias share the expression of some genes with Hardy fractions B and C. 
Collectively; the above analyses indicate that the murine leukemias maintain the 
transcription of certain genes that are important during the normal differentiation, likely 
reflecting the cell of origin of the leukemia. In addition, leukemias from Pax5
+/-
 mice that 
lost their second Pax5 allele during leukemia progression appear to reactivate genes that 
normally are expressed in early B-cells, in agreement with their immature 
immunophenotype. Importantly, although the leukemias maintain the activation of some 
genes that are expressed during normal differentiation, they exhibit profoundly different 
gene expression patterns as compared to their normal counterparts. Interestingly, N-Myc 
is the top differentially expressed gene between the leukemias and normal cells. 
Importantly, 10 wild-type and 10 Pax5 heterozygous leukemias were analyzed and half of 
the Pax5 hets were selected because of their immature immunophenotype.  Thus, it is 
important to consider that the Pax5 het group is not representative of the majority of 
Pax5 heterozygous leukemias. 
 
 
3.3.5 Gene Set Enrichment Analysis Reveals Murine Ph+ Leukemias Harbor Stem 
Cell-like Gene Expression Profile and Significantly Resemble Human Ph+ ALL 
 
 Our gene expression data demonstrate that as BCR-ABL1 leukemias lose a Pax5 
allele, the leukemia becomes more immature and consequently harbors a gene expression 
profile most similar to Hardy fraction B. In addition, the majority of B-progenitor ALLs 
arrested at a stage of development very similar to Hardy fraction B.  Taken together these 
data suggest that further characterization of Hardy fraction B cells may yield valuable 
insight into the mechanism by which Pax5 haploinsufficiency cooperates during BCR-
ABL1 induced leukemogenesis. 
  
 In an effort to better understand the gene expression program in BCR-ABL1 
leukemia cells we performed Gene Set Enrichment Analysis (GSEA). GSEA is a 
statistical algorithm that is used to interrogate a defined gene expression for the common 
expression of a set of a priori identified genes. We first generated a rank ordered gene list 
by comparing the gene expression profiles of our murine BCR-ABL1 leukemias versus all 
normal B-cell fractions.  Next, we walked along our rank ordered gene list with a series 
of currated genesets from the Molecular Signatures Database. Our GSEA revealed that 
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the core ESC-like geneset
82
 was significantly enriched in our murine BCR-ABL1 
leukemias (FDR=0.0869; Figure 3-12A). The core ESC-like gene set is a set of genes that 
are commonly expressed in both murine and human embryonic stem cells.  This geneset 
is comprised of 335 genes many of which are regulated by C-Myc.  Interestingly, the 
gene with the highest expression in our leukemias was N-Myc.  Taken together these data 
suggest that our BCR-ABL1 leukemias harbor a gene expression signature that is similar 
embryonic stem cells. Furthermore, our leukemias reveal high expression of N-Myc 
which may explain the similarities in expression.  Next we performed GSEA on normal 
B-cells by comparing Hardy fraction A to all others and B to all others, for all Hardy 
fractions.  We then assessed the enrichment of the core ESC-like geneset in any of the 
Hardy fractions. This GSEA revealed that the core ESC-like geneset was only 
significantly enriched in Hardy fraction B. Taken together, these data suggest that the 
stem cell signature identified in the leukemias results from an inherent signature retained 
by Hardy fraction B cells and further suggests that Pax5 loss may function to arrest B-cell 
development in such a way that the cell becomes more stem cell like. 
 
We next used GSEA to explore similarities between human and mouse BCR-
ABL1 ALLs. We generated a rank ordered gene list by comparing the gene expression 
profiles of human BCR-ABL1 ALL to all other B-progenitor ALL subtypes.  Next, we 
generated a murine BCR-ABL1 geneset by taking the top 100 genes that are expressed 
highly in our murine leukemias.  Subsequently, we found that the top 100 genes from our 
murine BCR-ABL1 leukemias were significantly enriched in human BCR-ABL1 ALLs 
suggesting that our murine model of BCR-ABL1 ALL is accurately recapitulating the 
human malignancy (FDR=0.161; Figure 3-12B). 
 
 
3.4 DISCUSSION 
 
 In summary, we have shown that Pax5 haploinsufficiency cooperates with BCR-
ABL1 during leukemogenesis.  We observed that Pax5
+/-
 BCR-ABL1 leukemias exhibit a 
more immature immunophenotype when compared to wild-type leukemias, including 
19% which harbored a Pre-pro B-cell immunophenotype.  Furthermore, we observed that 
our murine BCR-ABL1 leukemias acquire many of the same cooperating oncogenic 
lesions that are seen in human Ph+ ALLs, including recurrent copy number alterations of 
Pax5, Ink4a/Arf, and Pax5 sequence mutations. We have also shown that Arf 
haploinsufficiency further cooperates with Pax5 haploinsufficiency during BCR-ABL1 
induced leukemogenesis suggesting that these two pathways may further cooperate 
during leukemogenesis.  Importantly, in leukemias that started as Arf
+/-
, we were able to 
show that these leukemias continue to express Arf protein suggesting that the wild-type 
Arf allele is intact and Arf is functioning as a haploinsufficient tumor suppressor.  
However, there is the possibility that Pax5 loss may somehow impact the Arf/Mdm2/p53 
tumor suppressor pathway and may act as a second hit in this pathway, thereby 
eliminating the need to inactivate the wild-type Arf allele. Future studies assessing the 
interplay between Pax5 status and Arf expression will need to be performed. 
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Figure 3-12 Gene set enrichment analysis 
 
A, Gene Set Enrichment Analysis (GSEA) was used to evaluate enrichment of a host of 
genesets in murine BCR-ABL1 leukemias. A rank ordered gene list was generated by 
comparing murine BCR-ABL1 ALLs with normal Hardy fraction B cells (A-F).  GSEA 
was then performed and revealed that the geneset “Core-ESC-like module” was 
significantly enriched in the leukemias (FDR=0.0869), suggesting that the murine BCR-
ABL1 leukemias share similar expression of core embryonic stem cell genes. B, Gene Set 
Enrichment Analysis (GSEA) reveals that the top 100 overexpressed genes from Pax5
+/+
 
leukemias enrich in BCR-ABL1 signature of human B-ALL.  A rank ordered gene list was 
generated by comparing BCR-ABL1 ALLs with other B-lymphoid ALLs to define the 
BCR-ABL1 signature.  GSEA was then performed and the top 100 overexpressed genes 
from the Pax5
+/+
 leukemias were found to be enriched in the human BCR-ABL1 signature 
(FDR=0.161). 
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In an effort to gain mechanistic insight into the contribution that Pax5 loss may 
play during leukemogenesis we performed gene expression analysis and compared the 
expression profiles of Ph+ leukemias to their normal counterparts. Preliminary supervised 
gene expression analysis revealed that normal Hardy fraction stages of B-cell 
development harbor unique gene expression profiles.  Furthermore, our leukemias 
seemed to most closely resemble Hardy fraction B and C. A more sophisticated principal 
component analysis revealed that each stage of B-cell development has an identifiable, 
unique transcriptional program that differs from all other stages of B-cell development.  
We also observed that in comparison to normal B-cells, B-progenitor leukemias harbor a 
significantly different gene expression signature.  However, when we perform principal 
component analysis on normal B-cells and “lock” the analysis, and then add the 
leukemias onto this analysis we see that wild-type BCR-ABL1 leukemias are most similar 
to Hardy fractions B and C.  Interestingly, when one Pax5 allele is lost, all the leukemias 
now are most similar to Hardy fraction B suggesting that Pax5 haploinsufficiency 
contributes to a block in B-cell development.  Furthermore, gene set enrichment analysis 
revealed that a geneset comprised of 335 genes that are commonly expressed in murine 
and human embryonic stem cells is enriched in our murine BCR-ABL1 leukemias 
suggesting that our leukemias harbor a stem cell like gene expression profile. 
Interestingly, when we compare each Hardy fraction versus all other normal B-cells we 
see that the core embryonic stem cell-like geneset is only enriched in Hardy fraction B 
suggesting that Hardy fraction B cells harbor a latent stem cell like gene expression 
signature.  Interestingly, Pax5 is first expressed in Hardy fraction B and is absolutely 
necessary for B-cell commitment and development.
8,18
  In the absence of Pax5, B-cells 
are arrested at Hardy stage B and in the context of appropriate growth factors can 
dedifferentiate into many other hematopoietic lineages.
18
  Taken together, our data 
suggests that Hardy fraction B cells have a latent embryonic stem cell-like gene 
expression signature and that loss of Pax5 during leukemogenesis provides a block in B-
cell development at Hardy fraction B providing the developing leukemia with a more 
stem cell-like environment. It is very likely that Hardy fraction B cells are the last 
progenitor stage in the B-cell lineage and wild-type Pax5 expression is absolutely critical 
to commit B-cells to differentiate.  Pax5 is in this context a haploinsufficient tumor 
suppressor. Pax5 haploinsufficiency not only cooperates with BCR-ABL1 but also with 
other oncogenic lesions, like ENU, suggesting that its role as a haploinsufficient tumor 
suppressor is not limited to collaborating with the very strong BCR-ABL1 oncogene. 
 
Taken together, these data suggest that the lesions that have been identified by 
SNP analysis in human ALLs are cooperating oncogenic lesions and further examination 
of the pathways involved may yield important insights into future therapeutic avenues 
worth exploration in the global effort to cure ALL. 
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CHAPTER 4 
BCR-ABL1 LYMPHOBLASTIC LEUKEMIA IS CHARACTERIZED BY THE 
DELETION OF IKAROS

 
 
 
4.1 INTRODUCTION  
 
Acute lymphoblastic leukemia (ALL) comprises a heterogeneous group of 
disorders characterized by recurring chromosomal abnormalities including translocations, 
trisomies and deletions. An ALL subtype with especially poor prognosis is characterized 
by the presence of the Philadelphia chromosome arising from the t(9;22)(q34;q11.2) 
translocation, which encodes the constitutively activated BCR-ABL1 tyrosine kinase. 
BCR-ABL1 positive ALL constitutes 5% of paediatric B-progenitor ALL and 
approximately 40% of adult ALL.
21,22
 Expression of BCR-ABL1 is also the pathologic 
lesion underlying chronic myelogenous leukemia (CML).
20
 Data from murine studies 
demonstrates that expression of BCR-ABL1 in hematopoietic stem cells can alone induce 
a CML-like myeloproliferative disease, but cooperating oncogenic lesions are required 
for the generation of a blastic leukemia.
75,83
  Although the p210 and p190 BCR-ABL1 
fusions are most commonly found in CML and paediatric BCR-ABL1 ALL respectively, 
either fusion may be found in adult BCR-ABL1 ALL.
84
 Importantly, a number of genetic 
lesions including additional cytogenetic aberrations and mutations in tumour suppressor 
genes have been described in CML cases progressing to blast crisis.
85
 However, the 
specific lesions responsible for the generation of BCR-ABL1ALL and blastic 
transformation of CML remain incompletely understood.
85
 To identify cooperating 
oncogenic lesions in ALL, we recently performed a genome-wide analysis of paediatric 
ALL.
76
 This analysis identified an average of 6.8 genomic copy number alterations 
(CNA) in 9 BCR-ABL1 ALL cases, including deletions in genes that play a regulatory 
role in normal B cell development.  
 
 
4.2 MATERIALS AND METHODS 
 
 
4.2.1 Patients and Samples 
 
Two hundred eighty two patients with acute lymphoblastic leukemia (ALL) 
treated at St. Jude Children’s Research Hospital, 22 adult BCR-ABL1 ALL patients 
treated at the University of Chicago, and 49 samples obtained from 23 adult patients with 
chronic myeloid leukaemia (CML) treated at the Institute of Medical and Veterinary 
Science, Adelaide. The CML cohort included 24 chronic phase, 7 accelerated phase and 
15 blast crisis samples, and three samples obtained at complete cytogenetic response. All 
blast crisis samples were flow sorted to at least 90% blast purity prior to DNA extraction 
                                                 
 

 Adapted with permission. Mullighan C, Miller C, Radtke I, Phillips L, Dalton J, Ma J, White D, Hughes 
T, Le Beau M, Pui C, Relling M, Shurtleff S, Downing J.  BCR-ABL1 lymphoblastic leukaemia is 
characterized by the deletion of Ikaros. Nature 453, 110-114 (2008).
19
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using FACSVantage SE (with DiVa option) flow cytometers (BD Biosciences, San Jose, 
CA) and fluorescein isothiocyanate labeled CD45, allophycocyanin labeled CD33 and 
phycoerythrin labeled CD19 and CD13 antibodies (BD Biosciences). Germline tissue 
was obtained by also sorting the non-blast population in 7 cases. Informed consent for the 
use of leukemic cells for research was obtained from patients, parents or guardians in 
accordance with the Declaration of Helsinki, and study approval was obtained from the 
SJCRH institutional review board. 
 
 
4.2.2 Cell Lines Examined by SNP Array 
 
Thirty-six acute myeloid and lymphoid leukemia cell lines were genotyped using 
the Affymetrix Mapping 250k Sty and Nsp arrays. These were the ALL cell lines 380 
(MYC-IGH and BCL2-IGH B-precursor), 697 (TCF3-PBX1), AT1 (ETV6-RUNX1), 
BV173 (CML in lymphoid blast crisis), CCRF-CEM (TAL-SIL), Jurkat (T-ALL), 
Kasumi-2 (TCF3-PBX1), MHH-CALL-2 (hyperdiploid B-precursor ALL), MHH-CALL-
3 (TCF3-PBX1), MOLT3 (T-ALL), MOLT4 (T-ALL), NALM-6 (B-precursor ALL), 
OP1 (BCR-ABL1), Reh (ETV6-RUNX1), RS4;11 (MLL-AF4), SD1 (BCR-ABL1), SUP-
B15 (BCR-ABL1), TOM-1 (BCR-ABL1), U-937 (PICALM-AF10), UOCB1 (TCF3-HLF), 
YT (NK leukaemia); and the AML cell lines CMK (FAB M7), HL-60 (FAB M2), K-562 
(CML in myeloid blast crisis), Kasumi-1 (RUNX1-RUNX1T1), KG-1 (myelocytic 
leukaemia), ME-1 (CBFB-MYH11), ML-2 (MLL-AF6), M-07e (FAB M7), Mono Mac 6 
(MLL-AF9), MV4-11 (MLL-AF4), NB4 (PML-RARA), NOMO-1 (MLL-AF9), PL21 
(FAB M3), SKNO-1 (RUNX1-RUNX1T1) and THP-1 (FAB M5). Cell lines were 
obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen, 
Braunschweig, Germany; the American Type Culture Collection, Manassas, VA, from 
local institutional repositories, or were gifts from Olaf Heidenreich (SKNO-1) and Dario 
Campana (OP1). Cells were culture in accordance with previously published 
recommendations.
86
 The paediatric BCR-ABL1 B-precursor ALL cell line OP1
87
 was 
cultured in RPMI-1640 containing 100
 
units/ml penicillin, 100 µg/ml streptomycin,
 
2 mM 
glutamine and 10% fetal bovine serum. DNA was extracted from 5x10
6
 cells obtained 
during log phase growth after washing in PBS using the QIamp DNA blood mini kit 
(Qiagen, Valencia, CA). 
 
 
4.2.3 Single Nucleotide Polymorphism Microarray Analysis 
 
Collection and processing of diagnostic and remission bone marrow and 
peripheral blood samples for Affymetrix single nucleotide polymorphism microarray 
analysis has been previously reported in detail.
76
 Affymetrix 250K Sty and Nsp arrays 
were performed on all samples. 50k Hind 240 and 50k Xba 240 arrays were performed 
for 252 ALL samples. SNP array CEL and SNP call TXT files (generated by Affymetrix 
GTYPE 4.0 using the DM algorithm) have been deposited in NCBIs Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO 
Series accession numbers GSE9109-9113.  
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4.2.4 Fluorescence In Situ Hybridization 
 
Fluorescence in situ hybridization for IKZF1 deletion was performed using 
diagnostic bone marrow or peripheral blood leukaemic cells in Carnoy’s fixative as 
previously described.
76
 BAC clones CTD-2382L6 and CTC-791O3 (for IKZF1, Open 
Biosystems, Huntsville, AL) were labeled with fluorescein isothiocyanate, and control 
7q31 probes RP11-460K21 (Children’s Hospital Oakland Research Institute, Oakland, 
CA) and CTB-133K23 (Open Biosystems), were labeled with rhodamine. At least 100 
interphase nuclei were scored per case. 
 
 
4.2.5 IKZF1 PCR, Cloning, Quantitative PCR and Genomic Sequencing 
 
RNA was extracted and reverse transcribed using random hexamer primers and 
Superscript III (Invitrogen, Carlsbad, CA) as previously described.
76
 IKZF1 transcripts 
were amplified from cDNA using the Advantage 2 PCR enzyme (Clontech, Mountain 
View) as previously described
76
 using primers that anneal in exon 0 and 7 of IKZF1. PCR 
products were purified, and sequenced directly and after cloning into pGEM-T-Easy 
(Promega, Madison, WI). Genomic quantitative PCR for exons 1-7 of IKZF1, and real-
time PCR to quantify expression of Ik6 were performed as previously described.
76
 All 
primers and probes are listed in Supplementary Table 3. Genomic sequencing of IKZF1 
exons 0-7 in all ALL and CML samples was performed as previously described.
76
 
 
 
4.2.6 Western Blotting 
 
Whole cell lysates of 3-6x10
6
 leukemic cells were prepared and blotted as 
previously described
76
 using N- and C-terminus specific rabbit polyclonal Ikaros 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). 
 
 
4.2.7 Methylation Analysis 
 
Methylation status of the IKZF1 promoter CpG island (chr7:50121508-50121714) 
was performed using MALDI-TOF mass spectrometry of PCR-amplified, bisulfite 
modified genomic DNA extracted from leukemic cells as previously described.
49,76
 
 
 
4.2.8 Statistical Analysis 
 
Associations between ALL subtype and IKZF1 deletion frequency were 
calculated using the exact likelihood ratio test. Differences in Ik6 expression between 
IKZF1 3-6 and non-3-6 cases was assessed using the exact Wilcoxon-Mann-Whitney 
test. All P values reported are two-sided. Analyses were performed using StatXact v8.0.0 
(Cytel, Cambridge, MA). 
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4.3 RESULTS 
 
 
4.3.1 Ikaros is Commonly Deleted in BCR-ABL1 ALL 
 
To extend this analysis and identify lesions that distinguish CML from BCR-
ABL1 ALL, we have now examined DNA from leukemic samples from 304 pediatric and 
adult ALLs (254 B-progenitor, 50 T-lineage), including 21 pediatric and 22 adult BCR-
ABL1 ALL, and 23 adult CML cases. Samples were analyzed using the 250k Sty and Nsp 
Affymetrix SNP arrays (and also the 100K arrays for most cases). This identified a mean 
of 8.79 somatic CNA per BCR-ABL1 ALL case (range 1-26), with 1.44 gains (range 0-
13) and 7.33 losses (range 0-25). No significant differences were noted in the frequency 
of CNAs between paediatric and adult BCR-ABL1 ALL cases. The most frequent somatic 
CNA was deletion of IKZF1, which encodes the transcription factor Ikaros (Table 4-1). 
IKZF1 was deleted in 36 (83.7%) of 43 BCR-ABL1 ALL cases, including 76.2% of 
paediatric and 90.9% of adult BCR-ABL1 ALL cases. CDKN2A was deleted in 53.5% of 
BCR-ABL1 ALL cases, most of which (87.5%) also had deletions of IKZF1 (Table 4-1). 
Conversely, of the BCR-ABL1 ALL cases with IKZF1 deletions, 41.6% lacked CDKN2A 
alterations. Deletion of PAX5 occurred in 51% of BCR-ABL ALL cases, again with the 
majority also having a deletion of IKZF1 (95%) (Table 4-1). No other defining CNAs 
were identified in the rare BCR-ABL1 ALL cases that lacked a deletion of IKZF1.  
 
Ikaros is a member of a family of zinc finger nuclear proteins that is required for 
normal lymphoid development.
88-91
 Ikaros has a central DNA-binding domain consisting 
of four zinc fingers, and a homo- and heterodimerization domain consisting of the two C-
terminal zinc fingers
92
 (Figure 4-1A). Alternative splicing generates multiple Ikaros 
isoforms, several of which lack the N-terminal zinc fingers required for DNA binding; 
however, the physiological relevance of these isoforms in normal hematopoiesis remains 
unclear.
88-90,93
 The IKZF1 deletions identified in BCR-ABL1 ALL were predominantly 
mono-allelic and were limited to the gene in 25 cases, conclusively identifying IKZF1 as 
the genetic target (Figure 4-1B). In 19 cases the deletions were confined to a subset of 
internal IKZF1 exons, most commonly exons 3-6 (3-6; N=15). Importantly, the ∆3-6 
deletion is predicted to encode an Ikaros isoform that lacks the DNA-binding domain but 
retains the C-terminal zinc fingers. The IKZF1 deletions were confirmed by FISH and 
genomic quantitative PCR, and were in the predominant leukemic clone. Detailed 
analysis failed to reveal any evidence of either IKZF1 point mutations or inactivation of 
its promoter by CpG methylation in primary ALL samples. 
 
 
4.3.2 Ikaros Deletions Result in the Expression of a Dominant Negative Isoform Ik6  
 
The expression of aberrant, dominant negative Ikaros isoforms in B- and T-
lineage ALL has been previously reported by several groups,
94-101
 although alternative 
splicing has been reported to be the underlying mechanism.
102
 Importantly, the ∆3-6 
isoform of Ikaros has been shown to function as a dominant negative inhibitor of the 
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Table 4-1 Frequency of recurring DNA copy number abnormalities in ALL 
 
ALL subtype (N) IKZF1  CDKN2A PAX5 C20orf94 RB1 MEF2C EBF1 BTG1 DLEU FHIT ETV6 
B-progenitor (254)            
BCR-ABL1 (43) 36 23 22 10 8 6 6 6 4 4 3 
 - childhood  (21) 16 13 12 3 4 4 3 2 3 2 1 
 - adult  (22) 20 10 10 7 4 2 3 4 1 2 2 
Hypodiploid (10) 5 10 10 0 0 0 1 1 0 1 2 
Other B-ALL (75) 15 25 22 4 1 0 2 5 1 3 10 
High hyperdiploid (39) 2 8  4 1 3 0 0 0 5 0 3 
MLL-rearranged (22) 1 4 4 0 2 0 0 0 3 0 2 
TCF3-PBX1 (17) 0 6 7 0 2 0 0 0 2 0 0 
ETV6-RUNX1 (48) 0 14 16 6 2 0 5  7 4 6 33 
T-lineage (50) 2 36 5 1 6 1 3 0 3 0 4 
Total (304) 61 126 90 22 24 7 17 19 22 14 57 
P 6.6x10
-27
 7.4x10
-10
 1.4x10
-9
 7.0x10
-8
 1.1x10
-6
 0.0004 0.0247 1.5x10
-7
 2.6x10
-6
 0.0076 9.1x10
-15
 
 
The prevalence of recurring genomic abnormalities in BCR-ABL1 B-progenitor ALL identified by SNP array analysis is shown for 
each ALL subtype. The exact likelihood ratio P value for variation in the frequency of each lesion across ALL subtypes is shown. The 
DLEU region at 13q14 incorporates the miRNA genes MIRN16-1 and MIRN15A. 
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Figure 4-1 IKZF1 deletions in BCR-ABL1 ALL 
 
A, Domain structure of IKZF1. Exons 3-5 encode four N-terminal zinc fingers (black 
boxes) responsible for DNA binding. The C-terminal zinc fingers encoded by exon 7 are 
essential for homo- and heterodimerization. B, Genomic organization of IKZF1 and 
location of each of the 36 deletions observed in BCR-ABL1 B-progenitor ALL. Each line 
depicts the deletion(s) observed in each case. In five cases, two discontiguous deletions 
were observed. Hemizygous deletions are solid lines and homozygous deletions dashed. 
Arrows indicated deletions extending beyond the limits of the figure. The exact 
boundaries of the deletions were defined by genomic qPCR, and for IKZF1 3-6, by 
long-range genomic PCR (red arrow). C, dChipSNP raw log2 ratio copy number data 
depicting IKZF1 deletions for 29 BCR-ABL1 cases and 3 B-progenitor ALL cell lines. 
 71 
transcriptional activity of Ikaros and related family members.
92
 Moreover, mice 
homozygous for either an Ikzf1 null mutation
103
 or a dominant negative Ikzf1 mutation
67
  
exhibit profound defects in lymphoid development, and mice heterozygous for a 
dominant negative Ikzf1 mutation develop clonal T cell expansions and 
lymphoproliferative diseases,
69
 demonstrating that alteration in the level of Ikzf1 
expression is oncogenic.  
 
The high frequency of focal deletions in IKZF1 in BCR-ABL1 ALL suggests that 
expression of alternative IKZF1 transcripts may be the result of specific genetic lesions, 
and not alternative splicing of an intact gene. To further explore this possibility, we 
performed RT-PCR analysis for IKZF1 transcripts in 159 cases (Figure 4-2). This 
demonstrated that expression of the Ik6 transcript, which lacks exons 3-6, was 
exclusively observed in cases harboring the IKZF1 3-6 deletion (Figure 4-2B). 
Furthermore, we detected two novel Ikaros isoforms exclusively in cases with larger 
deletions; Ik9 in a case with deletion of exons 2-6, and Ik10 in three cases with deletion 
of exons 1-6 (Figure 4-2A-B). For each isoform, Ik6, 9 and 10, there was concordance 
between the transcripts detected by RT-PCR and the extent of deletion defined by SNP 
array and genomic PCR analysis (Figure 4-2B). Moreover, analysis of 22 IKZF1 3-6 
and 29 non-3-6 cases with a quantitative PCR assay specific for the Ik6 transcript 
confirmed that Ik6 expression was restricted to cases with the 3-6 deletion (P=6.41x10
-
15
). In addition, the Ik6 protein isoform was only detectable by western blotting in cases 
with a 3-6 IKZF1 deletion (Figure 4-2C). We also did not observe expression of Ik6 
following the enforced expression of BCR-ABL1 in Arf null or wild type murine 
hematopoietic precursors. Together, these data indicate that the expression of non-DNA 
binding Ikaros isoforms is due to IKZF1 genomic abnormalities, and not aberrant post-
transcriptional splicing induced by BCR-ABL1, as has been suggested.
102
 
 
 
4.3.3 Deletion of Ikaros is an Important Event in the Transformation of CML to 
Lymphoid Blast Crisis 
 
 To identify CNAs in CML, we performed SNP array analysis on 23 CML cases. 
In addition to chronic phase CML (CP-CML), we also examined matched accelerated 
phase (AP-CML, N=7) and blast crisis (BC-CML, N=15, 12 myeloid and 3 lymphoid) 
samples. This identified only 0.47 CNAs per CP-CML case (range 0-8), suggesting that 
BCR-ABL1 is sufficient to induce CML, but alone does not result in substantial genomic 
instability. Importantly, no recurrent lesions were identified. In contrast, there was a 
mean of 7.8 CNAs per BC-CML case (range 0-28), with IKZF1 deletions in four BC 
samples, including two of the three cases with lymphoid blast crisis (Figure 4-3A). Two 
of the IKZF1 deletions involved the entire gene (CML-#4-BC and #22-BC), one 3-6 
(CML-#1-BC, which was associated with Ik6 expression by RT-PCR) and one 3-7 
(CML-#7-BC). CML-#7-BC also had an IKZF1 nonsense mutation in the C-terminal zinc 
finger domain of exon 7 in the non-deleted allele (c.1520C>A, p.Ser507X, Figure 4-3B). 
One BC sample had a CDKN2A deletion, and four cases had CNAs involving PAX5 (two 
deletions, one internal amplification, one trisomy 9), with two of these also having IKZF1 
deletion. CNAs were identified in two AP-CML samples.
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Figure 4-2 Ikaros isoforms in ALL blasts 
 
A, Domain structure of the IKZF1 isoforms detected by RT-PCR, examples of which are 
shown in panel B. B, RT-PCR for IKZF1 transcripts (using exon 0 and 7 specific 
primers) in representative cases with various IKZF1 genomic abnormalities. Each case 
expressing an aberrant isoform had a corresponding IKZF1 genomic deletion. IKZF1 3-
6 was also detected in the BCR-ABL1 ALL cell lines SUP-B15 and OP1, and 1-6 in the 
ALL cell line 380. C, Western blotting for Ikaros using a C-terminus specific polyclonal 
antibody. Ik6 was only detectable in cases with IKZF13-6. The 1-6 and 2-6 deletions 
do not produce a detectable protein. In three cases with multiple focal hemizygous 
deletions involving different regions of IKZF1 (BCR-ABL-SNP-#26, -#29, and -#31), no 
wild type Ikaros was detectable by RT-PCR or western blotting, indicating that the 
deletions involve both copies of IKZF1 in each case.
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Figure 4-3 IKZF1 deletions in blast crisis CML 
 
A, dChipSNP log2ratio copy number heatmaps of four CML cases showing acquisition of 
IKZF1 deletions at progression to blast crisis. B-C, Pherograms of IKZF1 exon 7 
sequencing demonstrating acquisition of the c.1520C>A, p.Ser507X mutation at blast 
crisis in case CML-#7. As this case has a concomitant hemizygous IKZF1 deletion 
involving exon 7, the mutation appears homozygous.
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 These data demonstrate an increased burden of genomic aberrations during 
progression of CML, with IKZF1 mutation a frequent event in the transformation of CML 
to lymphoid blast crisis. 
 
 
4.3.4 Ikaros Deletions are Likely a Result of Aberrant RAG Activity 
 
To explore the mechanism responsible for the identified IKZF1 deletion, we 
sequenced the IKZF1 3-6 genomic breakpoints. The deletions were restricted to highly 
localized sequences in introns 2 and 6. Moreover, heptamer recombination signal 
sequences (RSSs) recognized by the RAG enzymes during V(D)J recombination
104
 were 
located immediately internal to the deletion breakpoints, and a variable number of 
additional nucleotides were present between the consensus intron 2 and 6 sequences, 
suggestive of the action of terminal deoxynucleotidyl transferase (TdT). Together, these 
data suggest that the IKZF1 3-6 deletion arises due to aberrant RAG-mediated 
recombination. 
 
 
4.4 DISCUSSION 
 
In summary, we have identified a high frequency of CNAs in BCR-ABL1 ALL 
and BC-CML, but not in CP-CML. We observed a near obligate deletion of IKZF1 in 
BCR-ABL1 ALL, with 83.7% of paediatric and adult cases containing deletions that lead 
to a reduction in dose and/or the expression of an altered Ikaros isoform. By contrast, 
deletion of IKZF1 was not detected in CP-CML, but was identified as an acquired lesion 
in 2 of 3 lymphoid BC-CML samples. These data, together with the low frequency of 
IKZF1 deletions in other pediatric B-progenitor ALL cases, and the lack of focal IKZF1 
aberrations in recently reported genomic analysis of non-hematopoietic tumors
105
 suggest 
that alterations in Ikaros directly contribute to the pathogenesis of BCR-ABL1 ALL. How 
reduced activity of Ikaros, and possibly that of other family members through the 
expression of dominant negative Ikaros isoforms, collaborates with BCR-ABL1 to induce 
lymphoblastic leukemia remains to be determined. Importantly, mice with attenuated 
Ikaros expression exhibit a partial block of B lymphoid maturation at the pro-B cell 
stage,
106
 suggesting that Ikaros loss may contribute to the arrested B lymphoid maturation 
in BCR-ABL1 ALL. However, the high co-occurrence of PAX5 deletions in many cases 
suggests that IKZF1 deletion contributes to transformation in additional ways. The 
frequent co-deletion of CDKN2A (encoding INK4A/ARF) with IKZF1 in BCR-ABL1 
ALL is a notable finding. This suggests that attenuated Ikaros activity may either 
collaborate with disruption of INK4A/ARF-mediated tumor suppression, or act through 
alternative uncharacterized tumor suppressor pathways in ALL. Furthermore, the 
identification of aberrant RAG-mediated recombination as the mechanism underlying 
deletions of IKZF1 suggests that the cellular target of this transforming event is 
downstream of the hematopoietic stem cell. Dissecting the contribution of altered Ikaros 
activity to BCR-ABL1 leukaemogenesis should not only provide valuable mechanistic 
insights, but will also help to determine if the presence of this genetic lesion can be used 
to gain a therapeutic advantage against this aggressive leukemia. 
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CHAPTER 5 
OVERALL SUMMARY AND FUTURE DIRECTIONS 
 
 
 Significant progress has been made in the treatment of ALL with cure rates 
approaching 90%.  Despite the significant advances in the treatment of children with 
ALL, 10% of children do not survive and many children endure significant complications 
associated with current therapy.  As a result, it is critical that the full complement of 
genetic mutations within ALL be identified so that therapy can be adjusted and improved 
in order to cure every child and to minimize therapy related complications as much as 
possible. 
  
 ALL is comprised of several distinct subtypes and in the majority of subtypes, the 
initiator or driver lesion is known.  In order to identify additional cooperating oncogenic 
mutations we have performed genome-wide SNP analysis on nearly 250 ALL cases.  The 
SNP analysis revealed that genes that are responsible for B-cell development and 
differentiation are mutated in 40% of B-progenitor ALLs.  These mutations include 
deletions, amplifications, translocations, and point mutations.  The most common target 
of mutation was the PAX5 gene which was found to be mutated in 32% of cases.  As 
discussed in chapter 2, there were several PAX5 mutations identified, the majority of 
which resulted in either hemizygous loss of the gene or in the production of a 
hypomorphic allele suggesting that PAX5 haploinsufficiency may be a cooperating lesion 
during leukemogenesis.  This result raises several questions for future study that have not 
been addressed in this dissertation.  We can clearly appreciate that PAX5 mutations are 
common in ALL but what are the effects that PAX5 mutations have on the normal 
function of the PAX5 protein?  Chapter 3 discusses work that has been done elucidating 
the finding that Pax5 haploinsufficiency cooperates with BCR-ABL1 during 
leukemogenesis.  However, there are additional mechanisms of PAX5 mutation in 
addition to hemizygous loss, including point mutation, internal truncation, and 
translocation.  It will be important to understand the effects that these PAX5 mutations 
have on normal PAX5 function. 
  
 In order to determine the effects that these mutations have on normal PAX5 
function we will need to introduce the various Pax5 mutants into Pax5
-/-
 B-cells.  The 
transduction experiments can be performed in vitro and the cells can then be evaluated 
for evidence of differentiation by flow cytometry, Southern or PCR analysis for 
immunoglobulin gene rearrangements, and bone marrow transplant assays for 
differentiation and tumorigenic potential.  The next logical progression of experiments 
would be to generate knock-in animals expressing one or more of the Pax5 mutations.  
By knocking in a Pax5 point mutation into the Pax5 locus we can ask several important 
questions.  First, is the mutation conducive to life, that is, does the presence of the 
mutation cause the death of the animal? Second, what is the spectrum of B-cell 
development within the bone marrow compartment of the animal?  Are there any off-site 
effects of the Pax5 mutation; does the mutation affect other tissues?  A knock in animal 
model will also be very important for future work because expression of the Pax5 
mutation is controlled by the Pax5 locus and not a viral LTR which results in abnormally 
 77 
high expression of the associated gene.  Thus, is Pax5 mutant expression at normal levels 
that is sensitive to normal cellular signaling cues, sufficient for normal B-cell 
development or is it insufficient or perhaps even oncogenic?  This series of experiments 
is critical because it is very possible that expression of hypomorphic allele at high levels 
is enough to confer normal Pax5 effects, whereas, expression of the same hypomorphic 
allele at normal physiologic levels may result in a block in B-cell development. 
  
 The generation of knock in animals that harbor Ikaros mutations will also be an 
important series of experiments to perform.  We have shown in chapter 4 that deletions of 
the IKZF1 (Ikaros) gene are almost a required event in Ph+ leukemia.  Not only do most 
BCR-ABL1 leukemias harbor deletions of the Ikaros gene, but we have shown in a recent 
study that deletion of Ikaros is a negative prognostic indicator in ALL.
107
  Because many 
of the Ikaros deletions result in internally truncated mutants that are expected to behave 
as dominant negative inhibitors of normal Ikaros function, it will be important to generate 
an Ikaros mutant knock in animal model.  Again, by knocking the mutant Ikaros allele 
into the normal germline Ikaros locus we will be able to better appreciate the changes 
associated with the mutant allele.  We will ask questions like what are the consequences 
of Ikaros mutant; how does it affect normal hematopoiesis?  If the Ikaros mutants are in 
fact dominant negative inhibitors of normal Ikaros function then we will be able to asses 
those effects by performing DNA binding assays, transactivation assays, and Western 
blot analyses to determine the effects that the mutant has alone and the effects that it has 
on normal Ikaros function.  Additional studies regarding the leukemogenic effects of the 
Ikaros mutant knock-in, as well as, cooperation with BCR-ABL1 or other oncogenes will 
be of great interest. 
 
Importantly, many pediatric ALL cases harbor mutations of both PAX5 and Ikaros 
suggesting that multiple lesions within the B-cell development and differentiation 
pathway may cooperate during leukemogenesis.  Once the generation of both the PAX5 
and Ikaros knock-in animals is completed then these models can then be crossed and 
analyzed for effects on the hematopoietic system. It will be important to assess the ability 
of these mutations to cooperate to impair B-cell development both in the presence of an 
oncogene like BCR-ABL1 and in the absence of any oncogene.  The results of these 
experiments will help in our understanding of exactly how the loss of PAX5 or Ikaros 
really contributes to the development of ALL. 
 
In chapter 3 we discussed some of the insights we have gained into how the loss 
Pax5 may contribute to the development of ALL.  We discussed the previous findings 
that during normal B-cell development, as defined by Hardy fraction analysis, Pax5 
expression in turned on in fraction B and remains expressed in mature circulating B-
lymphocytes.  If one allele of Pax5 is lost then the gene expression profiles of all Hardy 
fractions from B distally change.  Even more impressive is the loss of both Pax5 alleles 
which completely arrest B-cell development at Hardy fraction B.  We have expanded the 
previously published data on the transcriptional networks that function during B-cell 
development.  Our gene expression profiling of B-cell development has revealed a 
significant increase in the number and scope of genes that are regulated by Pax5 as 
defined by changes in the gene expression profiles of Pax5 haploinsufficient and null B-
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cells.  Another important future experiment will be to elucidate which Pax5 responsive 
genes are primary targets by performing ChIP-sequencing analysis.  We have also shown 
using principal component analysis and gene set enrichment analysis that Hardy fraction 
B is enriched for a set of genes commonly expressed in embryonic stem cells.  It is no 
surprise then, that in pre-B leukemias, the stage of developmental arrest is Hardy fraction 
B, where there is expression of a set of stem cell genes.  The enrichment of this core 
ESC-like geneset was also seen in our murine leukemias further supporting the link 
between Hardy fraction B arrest and leukemogenic potential. I would speculate that the 
loss of Pax5 in the context of BCR-ABL1 expression confers a block in B-cell 
development sufficient to prevent the leukemia from differentiating beyond Hardy 
fraction B and, as a result, arrests the leukemia at a stage of development that retains a 
stem cell-like phenotype. 
 
Interestingly, leukemias that started as Pax5
+/-
 Arf
+/-
 still retained expression of 
the wild-type Arf allele at the protein level suggesting that the two pathways regulated by 
Pax5 and Arf somehow cooperate during leukemogenesis. Arf has long been proposed to 
be a prototypical two-hit tumor suppressor. And there is some evidence that suggests, in 
the context of BCR-ABL1, that if one Arf allele is lost then both Arf alleles will be lost 
during leukemogenesis
75
. Our data would suggest that in the context of Pax5 
haploinsufficiency, Arf haploinsufficiency cooperates and the wild-type Arf allele is 
intact suggesting that loss of both Arf alleles is not necessary unless Pax5 somehow 
regulates the Arf locus. If Pax5 were found to regulate Arf expression then this would 
explain a possible mechanism by which Pax5 haploinsufficiency cooperates with BCR-
ABL1 during leukemogenesis; by acting as a function hit to the Arf/Mdm2/p53 tumor 
suppressor pathway. Future studies aimed at elucidating the possible role that Pax5 has in 
regulating the Arf/Mdm2/p53 pathway will provide much needed insight. 
 
In order to elucidate the role that Pax5 haploinsufficiency plays in regulating the 
Arf tumor suppressor pathway we will perform a series of in vitro studies aimed at 
assessing Arf protein levels in BCR-ABL1 positive B-cells of varying Pax5 genotype. 
Specifically, we will transduce total bone marrow from wild-type, Pax5
+/-
, Arf
+/-
 animals 
with ecotropic retrovirus harboring the BCR-ABL1 oncogene using the cationic polymer 
polybrene.  Transduced bone marrow cells will then be cultured for seven days during 
which time BCR-ABL1 expressing B-cell cultures will develop.  Upon maturation of the 
B-cell cultures, five million cells will be harvested for western blot and quantitative RT-
PCR analysis.  The relative level of Arf protein and Arf transcript will be assessed and 
compared from wild-type and Pax5
+/-
 cultures, allowing us to determine the effect that 
hemizygous loss of Pax5 has on Arf expression at the transcript and protein level. 
 
Should we find that Pax5 haploinsufficiency does affect the level of Arf 
expression in vitro then further experiments will be performed in vivo. We will harvest B-
cells from wild-type, Pax5
+/-
, Pax5
-/-
, Arf
+/- 
and Pax5
+/-
 Arf
+/- 
animals and use protein and 
RNA extracted from these cells in the same series of analyses in order to determine the 
effects that Pax5 dose has on Arf expression. This series of experiments will allow us to 
determine the effects that Pax5 has on Arf expression during normal development in the 
absence of BCR-ABL1 signaling. Additionally, using a Pax5 antibody directed at the 
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DNA binding domain, we will perform chromatin imunoprecipitation (ChIP) experiments 
in order to determine whether the changes in Arf expression is due to direct Pax5 binding 
to the Arf promoter or due to down-stream signaling effects. This series of experiments 
will be performed by harvesting B-cells from wild-type, Pax5
+/-
, Pax5
-/-
, Arf
+/- 
and Pax5
+/-
 
Arf
+/- 
animals and subjecting them to a cross-linking reagent in order to actively cross-
link transcription factors like Pax5 to their DNA targets.  Cross-linked cells are then 
sonicated in order to shear the chromatin into smaller fragments and then the cross-links 
are reversed, DNA is extracted, and quantitative genomic PCR is performed using assays 
designed for the Arf promoter as well as a control assay designed for the known Pax5 
targets CD19 and Blnk. Analysis of the relative enrichment of Arf promoter to either the 
CD19 or Blnk promoters will allow us to determine if Pax5 directly binds to the Arf 
promoter. 
 
In summary, our work to elucidate cooperating oncogenic lesions in pediatric 
ALL has been very fruitful. Further work validating that these secondary oncogenic 
lesions cooperate has shown that the lesions we have identified are real cooperating 
lesions. Future work aimed at describing the mechanism by which these lesions cooperate 
will be of vital importance if we are to progress toward somehow targeting these 
dysregulated pathways therapeutically in an effort to bring Danny Thomas’ profound 
mission statement to pass “That no child should die in the dawn of life”. 
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